Updated on 2025/12/17

写真a

 
OKAHISA Yuko
 
Organization
Scheduled update Lecturer
Position
Lecturer
External link

Degree

  • 医学博士 ( 2010.3   岡山大学 )

  • Dr. of Medical Science ( Okayama University )

Research Areas

  • Life Science / Psychiatry

Education

  • 岡山大学大学院    

    2004 - 2010

    　 More details

  • Okayama University   医学部   医学科

    1995 - 2001

    　 More details

Research History

  • 岡山大学病院   講師

    2023.2

    　 More details

  • 岡山大学病院   助教

    2011 - 2023.1

    　 More details

  • 岡山大学病院   医員

    2010 - 2011

    　 More details

  • 岡山大学大学院

    2005 - 2010

    　 More details

  • 倉敷中央病院

    2004 - 2005

    　 More details

  • 国立岩国病院

    2002 - 2004

    　 More details

  • 岡山大学医学部附属病院

    2001 - 2002

    　 More details

▼display all

 

Papers

  • Metaverse Support Groups for LGBTQ+ Youth: An Observational Study on Safety, Self-Expression, and Early Intervention

    Joe Hasei, Yosuke Matsumoto, Hiroki Kawai, Yuko Okahisa, Manabu Takaki, Toshifumi Ozaki

    Journal of Metaverse   2025.12

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.57019/jmv.1639701

    researchmap

  • Effect modification in therapeutic impact of nalmefene on alcohol dependence by ADH1B polymorphism: A secondary analysis of a Japanese randomized clinical trial. International journal

    Nozomu Hashimoto, Manabu Takaki, Yoshitsugu Kojima, Izuru Nakamura, Daisuke D Ikeda, Shinji Sakamoto, Yuko Okahisa, Soshi Takao, Keitaro Matsuo

    Addiction (Abingdon, England)   120 ( 12 )   2423 - 2434   2025.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND AND AIMS: The association between alcohol-metabolizing enzyme polymorphisms and treatment response to nalmefene for alcohol dependence has not been studied. We aimed to determine whether alcohol-metabolizing enzyme polymorphisms, specifically ADH1B rs1229984 and ALDH2 rs671, modify the treatment response to nalmefene for alcohol dependence. DESIGN: Secondary analysis of a Japanese randomized clinical trial, in which participants were randomly assigned (4:3:4) to placebo, 10 mg nalmefene or 20 mg nalmefene groups for 24 weeks, accompanied by a brief psychosocial intervention. SETTING: 80 addiction outpatient clinics across Japan. PARTICIPANTS: A subset of 531 individuals (mean age 49.2 years, standard deviation 11.5; 69.9% male), including 196 in the placebo group and 335 in the nalmefene group, who agreed to DNA preservation and had available DNA data between February 2015 and July 2016. MEASUREMENTS: Genotyping was performed to determine ADH1B rs1229984 polymorphism (AA, AG, GG) and ALDH2 rs671 polymorphism (GG, GA, AA) in participants. Primary endpoint was change from baseline in monthly heavy drinking days (HDD, days/month) over the 24 treatment weeks. The key secondary endpoint was change from baseline in daily total alcohol consumption (TAC, g/day) over the 24 treatment weeks. FINDINGS: A mixed-effects model for repeated measures analyses showed a statistically significant gene-treatment interaction with ADH1B rs1229984 for TAC [10.71 (95% confidence interval = 4.03-17.39) g/day, P = 0.002], but not for HDD [1.65 (-0.38 to 3.67) days/month, P = 0.110]: as the G allele of rs1229984 increased, the efficacy regarding TAC decreased. In contrast, no statistically significant gene-treatment interaction was seen with ALDH2 rs671 for either TAC [4.46 (-7.88 to 16.80) g/day, P = 0.478] or HDD [-0.91 (-4.60 to 2.78) days/month, P = 0.630]. In the ADH1B rs1229984 variant, the number needed to treat for two category shifts in drinking risk level, as defined by the World Health Organization, was 3.7 for AA carriers, 6.6 for AG carriers and 18.5 for GG carriers. CONCLUSIONS: The ADH1B rs1229984 polymorphism appears to moderate the response to nalmefene in Japanese patients with alcohol dependence. Specifically, nalmefene appears to show efficacy in individuals with the ADH1B rs1229984 AA genotype.

    DOI： 10.1111/add.70160

    PubMed

    researchmap

  • DSOK-0011 Potentially Regulates Circadian Misalignment and Affects Gut Microbiota Composition in Activity-Based Anorexia Model. International journal

    Hiroki Kawai, Nanami Wada, Shinji Sakamoto, Kenji Miyazaki, Taro Kato, Yoshihiro Horiuchi, Hiroshi Kirii, Hoang Duy Nguyen, Kenji Hinotsu, Yoshio Ohya, Takahiro Asada, Akiyoshi Yokode, Yuko Okahisa, Haruko Miyazaki, Toshitaka Oohashi, Manabu Takaki

    The International journal of eating disorders   2025.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: Anorexia nervosa (AN) is a metabolic-psychiatric disorder characterized by severe weight loss, hypercortisolemia, and hypothalamic-pituitary-adrenal (HPA) axis activation. In this study, we investigated the effect of inhibiting cortisol regeneration via the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) on the pathophysiology of AN. METHOD: Female C57BL/6J mice underwent a 7-day activity-based anorexia (ABA) paradigm, involving 3 h daily feeding and free access to wheels, until 25% body weight loss or experiment completion. Mice were orally treated once daily with a potent 11β-HSD1 inhibitor, DSOK-0011, or vehicle. Body weight, food intake, and activity transitions were recorded; plasma corticosterone and cholesterol levels were measured using a fluorometric assay; gut microbiota were analyzed using 16S rRNA sequencing; and hippocampal glial cells were analyzed using immunohistochemistry. RESULTS: DSOK-0011-treated mice exhibited a modest but significant increase in postprandial wheel-running activity compared to baseline (4-5 p.m., p = 0.018; 5-6 p.m., p = 0.043), whereas vehicle-treated mice showed higher preprandial activity (9-10 a.m., p = 0.0229). Gut microbiota analysis revealed increased alpha diversity in ABA mice, with a specific enrichment of the Lachnospiraceae family in the DSOK-0011 group. However, DSOK-0011 did not significantly affect body weight, food intake, corticosterone, and lipid levels, or hippocampal glial cell populations. CONCLUSION: Inhibition of 11β-HSD1 by DSOK-0011 was associated with microbiota alterations and subtle shifts in activity timing under energy-deficient conditions. These findings suggest that peripheral glucocorticoid metabolism may influence microbial and behavioral responses in the ABA model, although its metabolic impact appears limited in the acute phase.

    DOI： 10.1002/eat.24557

    PubMed

    researchmap

  • Occupational therapist-guided exercise increased white blood cell and neutrophil counts during clozapine treatment: A case report. International journal

    Kenji Hinotsu, Shinji Sakamoto, Hiroki Kawai, Yoshio Ohya, Akiyoshi Yokode, Takahiro Asada, Yuko Okahisa, Manabu Takaki

    PCN reports : psychiatry and clinical neurosciences   4 ( 3 )   e70167   2025.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Moderate exercise increases white blood cells and neutrophils. However, there are no reports on the relationship between exercise intensity and these cells. We observed a patient taking clozapine whose white blood cell and neutrophil counts were borderline. Supervised exercise therapy with an occupational therapist stabilized these counts. CASE PRESENTATION: A 50-year-old woman with treatment-resistant schizophrenia was prescribed clozapine. By Day 63, the clozapine dosage had been increased to 450 mg/day. Additionally, she was advised to perform a 30-min walking exercise program 1 h before blood tests. Exercise therapy supervised by an occupational therapist was performed eight times, and self-training was performed five times. Exercise intensity was monitored using the Borg Scale for subjective evaluation and the Karvonen formula for objective evaluation. Supervised exercise therapy with an occupational therapist resulted in greater increases on the Borg Scale and Karvonen formula than did self-training. It also induced increases in white blood cells and neutrophils. Her psychiatric symptoms improved, and she was discharged on Day 71. A blood test taken after discharge revealed that her white blood cell and neutrophil counts were within the normal range and she continued to take clozapine for 2 years. She has since been able to enjoy a calm and relaxed life at home. CONCLUSION: Exercise involving subjective and objective evaluation by an occupational therapist effectively increased white blood cells and neutrophils during clozapine treatment. Supervised exercise therapy by an occupational therapist is important when self-exercise is insufficient for continuing clozapine treatment.

    DOI： 10.1002/pcn5.70167

    PubMed

    researchmap

  • 【精神疾患と神経炎症】自己免疫性精神病総論 精神疾患

    高木 学, 岡久 祐子, 酒本 真次, 河合 弘樹, 樋之津 健二, 和田 菜那美, 山田 了士

    臨床精神医学   53 ( 4 )   525 - 532   2024.4

    　More details

    Language：Japanese   Publisher：(株)アークメディア  

    researchmap

  • 【よくわかる! 精神疾患対応 これ1冊-内科医と精神科医の連携のために】(第2部)精神科との連携が特に必要な領域 抗NMDA受容体抗体脳炎等の辺縁系脳炎

    高木 学, 岡久 祐子, 酒本 真次

    診断と治療   112 ( Suppl. )   103 - 107   2024.3

    　More details

  • 【抗体介在性自己免疫性脳炎と精神医学】自己免疫性精神病 岡山大学病院における知見を含めて

    高木 学, 岡久 祐子, 酒本 真次, 樋之津 健二, 河合 弘樹, 来住 由樹, 山田 了士

    精神神経学雑誌   126 ( 2 )   114 - 125   2024.2

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 【脳画像所見を日常臨床に活かすには】自己免疫性脳炎と脳画像解析

    酒本 真次, 樋之津 健二, 河合 弘樹, 和田 菜那美, 岡久 祐子, 高木 学

    精神科   43 ( 3 )   294 - 303   2023.9

    　More details

    Language：Japanese   Publisher：(有)科学評論社  

    researchmap

  • Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting Reviewed

    Tomonari Hosokawa, Chikara Miyaji, Yusaku Yoshimura, Kenji Washida, Yuji Yada, Shinji Sakamoto, Yuko Okahisa, Soshi Takao, Akira Nomura, Yoshiki Kishi, Toshiki Harada, Manabu Takaki, Toshihiko Takeda, Norihito Yamada

    Psychopharmacology   2023.7

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1007/s00213-023-06407-6

    researchmap

    Other Link： https://link.springer.com/article/10.1007/s00213-023-06407-6/fulltext.html

  • Initial Outcomes of the Safe and Sound Protocol on Patients with Adult Autism Spectrum Disorder: Exploratory Pilot Study. Reviewed International journal

    Hiroki Kawai, Makiko Kishimoto, Yuko Okahisa, Shinji Sakamoto, Seishi Terada, Manabu Takaki

    International journal of environmental research and public health   20 ( 6 )   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Sensory impairments are common features of autism spectrum disorder (ASD) and are associated with its social impairments. However, there is no established treatment for these impairments in adults with ASD. The Safe & Sound Protocol (SSP) is a listening program designed to improve social communication skills by reducing auditory hypersensitivity. We investigated the effectiveness of the SSP for adults with ASD. We administered the SSP to six participants with ASD aged 21-44 years old, and the effects were assessed using the Social Responsiveness Scale, Second Edition (SRS-2). Secondary outcomes were assessed using the Center for Epidemiological Studies Depression Scale (CES-D), State-Trait Anxiety Inventory (STAI), WHO Quality of Life 26 (WHOQOL-BREF), and Adolescent/Adult Sensory Profile (A/ASP). In this study, only the Social Awareness scale of the SRS-2 Family-Report showed a significant improvement after the intervention. In addition, it was significantly correlated with physical health of WHOQOL-BREF (r = -0.577, p = 0.012), state and trait anxiety of STAI (r = 0.576, p = 0.012; r = 0.708, p = 0.00009, respectively), and CES-D (r = 0.465, p = 0.05). In conclusion, the SSP has a partial effect on social impairments in adults with ASD, specifically on the Social Awareness subscale of the SRS-2.

    DOI： 10.3390/ijerph20064862

    PubMed

    researchmap

  • The validity of atypical psychosis diagnostic criteria to detect anti-NMDA receptor encephalitis with psychiatric symptoms Reviewed

    Kenji Hinotsu, Chikara Miyaji, Yuji Yada, Hiroki Kawai, Shinji Sakamoto, Yuko Okahisa, Ko Tsutsui, Takashi Kanbayashi, Keiko Tanaka, Soshi Takao, Yoshiki Kishi, Manabu Takaki, Norihito Yamada

    Schizophrenia Research   248   292 - 299   2022.10

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.schres.2022.08.024

    researchmap

  • アルコール依存症に対するナルメフェンの無作為化比較試験における臨床的モデレーターについて 探索的分析

    橋本 望, 土生 裕, 高尾 総司, 酒本 真次, 岡久 祐子, 松尾 恵太郎, 高木 学, 来住 由樹, 山田 了士

    日本アルコール・薬物医学会雑誌   57 ( 4 )   239 - 239   2022.8

    　More details

    Language：Japanese   Publisher：(一社)日本アルコール・アディクション医学会  

    researchmap

  • Transdiagnostic comparisons of intellectual abilities and work outcome in patients with mental disorders: multicentre study. Reviewed International journal

    Chika Sumiyoshi, Kazutaka Ohi, Haruo Fujino, Hidenaga Yamamori, Michiko Fujimoto, Yuka Yasuda, Yota Uno, Junichi Takahashi, Kentaro Morita, Asuka Katsuki, Maeri Yamamoto, Yuko Okahisa, Ayumi Sata, Eiichi Katsumoto, Michihiko Koeda, Yoji Hirano, Masahito Nakataki, Junya Matsumoto, Kenichiro Miura, Naoki Hashimoto, Manabu Makinodan, Tsutomu Takahashi, Kiyotaka Nemoto, Toshifumi Kishimoto, Michio Suzuki, Tomiki Sumiyoshi, Ryota Hashimoto

    BJPsych open   8 ( 4 )   e98   2022.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Cognitive impairment is common in people with mental disorders, leading to transdiagnostic classification based on cognitive characteristics. However, few studies have used this approach for intellectual abilities and functional outcomes. AIMS: The present study aimed to classify people with mental disorders based on intellectual abilities and functional outcomes in a data-driven manner. METHOD: Seven hundred and forty-nine patients diagnosed with schizophrenia, bipolar disorder, major depression disorder or autism spectrum disorder and 1030 healthy control subjects were recruited from facilities in various regions of Japan. Two independent k-means cluster analyses were performed. First, intelligence variables (current estimated IQ, premorbid IQ, and IQ discrepancy) were included. Second, number of work hours per week was included instead of premorbid IQ. RESULTS: Four clusters were identified in the two analyses. These clusters were specifically characterised in terms of IQ discrepancy in the first cluster analysis, whereas the work variable was the most salient feature in the second cluster analysis. Distributions of clinical diagnoses in the two cluster analyses showed that all diagnoses were unevenly represented across the clusters. CONCLUSIONS: Intellectual abilities and work outcomes are effective classifiers in transdiagnostic approaches. The results of our study also suggest the importance of diagnosis-specific strategies to support functional recovery in people with mental disorders.

    DOI： 10.1192/bjo.2022.50

    PubMed

    researchmap

  • Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis. Reviewed International journal

    Nozomu Hashimoto, Hiroshi Habu, Soshi Takao, Shinji Sakamoto, Yuko Okahisa, Keitaro Matsuo, Manabu Takaki, Yoshiki Kishi, Norihito Yamada

    Drug and alcohol dependence   233   109365 - 109365   2022.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Nalmefene is the only medication marketed to reduce the consumption of alcohol in patients with alcohol dependence, but it remains unclear which patients could most benefit from it. This study aimed to identify clinical moderators that affect treatment response to nalmefene in patients with alcohol dependence. METHODS: In a multicenter, randomized, controlled, double-blind, phase 3 study of nalmefene on Japanese patients with alcohol dependence, the relationship between the reduction of heavy drinking days (HDD) and total alcohol consumption (TAC) at 12 and 24 weeks of treatment and baseline variables of the participants were analyzed in a linear regression and multiple adjusted analysis. RESULTS: Age < 65, no family history of problem drinking, age at onset of problem drinking ≥ 25, and not currently smoking were possible positive moderators. Nalmefene showed a significant HDD reduction in patients with age < 65 or no family history of problem drinking, and a significant TAC reduction in patients with age at onset of problem drinking ≥ 25 or who were not currently smoking. After multiple adjusted analyses, age < 65 (p = .028), no family history of problem drinking (p = .047), and age at onset of problem drinking ≥ 25 (p = .030) were statistically significant. Not currently smoking (p = .071) was marginally significant. In combination, these moderators indicated synergistic effects. CONCLUSIONS: Alcohol-dependent patients with favorable prognostic factors such as non-smoking status, no family history of problem drinking, and a late-onset of problem drinking selectively benefit from nalmefene. Further research is needed to validate these exploratory results.

    DOI： 10.1016/j.drugalcdep.2022.109365

    PubMed

    researchmap

  • 対人関係発達指導法(RDI)による自閉症児への療育 ケースシリーズ

    岸本 真希子, 河合 弘樹, 酒本 真次, 岡久 祐子, 高木 学, 山田 了士

    精神神経学雑誌   124 ( 4付録 )   S - 537   2022.4

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • Association between depression in chronic phase and future clinical outcome of patients with schizophrenia. Reviewed International journal

    Yuto Yamada, Yusuke Yamauchi, Shinji Sakamoto, Masaki Fujiwara, Yuko Okahisa, Soshi Takao, Manabu Takaki, Norihito Yamada

    Psychopharmacology   239 ( 3 )   965 - 975   2022.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    RATIONALE: Depression in schizophrenia is an important symptom. We investigated whether depression and suicidal symptoms in the chronic phase are related to remote future clinical outcomes in patients with schizophrenia and whether psychotropics improved clinical outcomes. OBJECTIVES: The subjects included 462 outpatients of working age (15 to 64 years old) with schizophrenia treated at Okayama University Hospital from January 2010 to December 2011. We investigated the relationship between the Clinical Global Impression-Severity score at the last visit (average 19.2 years) and the existence of previous depression, suicidal ideas, and suicide attempts. We adjusted by several possible confounders including medical history using multiple regression analysis or logistic regression analysis. RESULTS: Of 462 patients, 168 (36.4%) presented with depression 2 years after schizophrenia onset. A history of suicidal ideas and attempts was related to worse clinical outcome. In males, a history of depression was related to worse clinical outcome, but not in females. Lithium carbonate was related to better clinical outcome in all schizophrenia patients with depression, especially in males. Treatment with antidepressants was related to better clinical outcome only in males. CONCLUSIONS: A history of depression or suicidal symptoms in the chronic phase predicted the future worse clinical outcome in patients with schizophrenia. The administration of lithium carbonate or antidepressants might be recommended, especially to male schizophrenia patients with depression.

    DOI： 10.1007/s00213-022-06099-4

    PubMed

    researchmap

  • A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine. Reviewed International journal

    Manabu Takaki, Yuji Yada, Shinji Sakamoto, Masaki Fujiwara, Yuko Okahisa, Norihito Yamada

    Journal of clinical psychopharmacology   2022.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/JCP.0000000000001527

    PubMed

    researchmap

  • Mirtazapine Was Effective for a Patient With Benzodiazepine Dependence. Reviewed International journal

    Manabu Takaki, Ryo Ishikawa, Shinji Sakamoto, Nozomu Hashimoto, Yuko Okahisa, Norihito Yamada

    Clinical neuropharmacology   2021.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: Benzodiazepine (BZD) dependence has become a social problem and results in poor outcomes. Only a few evidence-based treatments for pharmacotherapy, including antidepressants, are recommended. METHODS: We reported about a 71-year-old man with onset of blindness at 50 years of age due to pigmentary degeneration of the retina developed insomnia at age 59 years, characterized by nocturnal and early morning awakenings. RESULTS: Mirtazapine was effective to not only treat sleep disturbance but also a craving for BZD. CONCLUSIONS: The increases of dopamine, norepinephrine, and serotonin signaling by mirtazapine may be related to the effectiveness in reducing BZD dependence.

    DOI： 10.1097/WNF.0000000000000488

    PubMed

    researchmap

  • Impairment of early neuronal maturation in anti-NMDA-receptor encephalitis Reviewed

    Sojiro Okamoto, Manabu Takaki, Kenji Hinotsu, Hiroki Kawai, Shinji Sakamoto, Yuko Okahisa, Soshi Takao, Ko Tsutsui, Takashi Kanbayashi, Keiko Tanaka, Norihito Yamada

    PSYCHOPHARMACOLOGY   2021.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00213-021-06036-x

    Web of Science

    researchmap

  • 抗体介在性自己免疫性脳炎と精神疾患 自己免疫性精神病 発症機序と多彩な精神症状

    高木 学, 酒本 真次, 岡久 祐子, 山田 了士

    精神神経学雑誌   ( 2021特別号 )   S294 - S294   2021.9

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study Reviewed

    Yuji Yada, Kohei Kitagawa, Shinji Sakamoto, Atsushi Ozawa, Akihiro Nakada, Hiroko Kashiwagi, Yuko Okahisa, Soshi Takao, Manabu Takaki, Yoshiki Kishi, Norihito Yamada

    ACTA PSYCHIATRICA SCANDINAVICA   143 ( 3 )   227 - 237   2021.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/acps.13264

    Web of Science

    researchmap

  • Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. Reviewed International journal

    Yutaka Mizuki, Shinji Sakamoto, Yuko Okahisa, Yuji Yada, Nozomu Hashimoto, Manabu Takaki, Norihito Yamada

    The international journal of neuropsychopharmacology   24 ( 5 )   367 - 382   2020.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The mortality rate of patients with schizophrenia is high, and life expectancy is shorter by 10 to 20 years. Metabolic abnormalities including type 2 diabetes mellitus (T2DM) are among the main reasons. The prevalence of T2DM in patients with schizophrenia may be epidemiologically frequent because antipsychotics induce weight gain as a side effect and the cognitive dysfunction of patients with schizophrenia relates to a disordered lifestyle, poor diet, and low socioeconomic status. Apart from these common risk factors and risk factors unique to schizophrenia, accumulating evidence suggests the existence of common susceptibility genes between schizophrenia and T2DM. Functional proteins translated from common genetic susceptibility genes are known to regulate neuronal development in the brain and insulin in the pancreas through several common cascades. In this review, we discuss common susceptibility genes, functional cascades, and the relationship between schizophrenia and T2DM. Many genetic and epidemiological studies have reliably associated the comorbidity of schizophrenia and T2DM, and it is probably safe to think that common cascades and mechanisms suspected from common genes' functions are related to the onset of both schizophrenia and T2DM. On the other hand, even when genetic analyses are performed on a relatively large number of comorbid patients, the results are sometimes inconsistent, and susceptibility genes may carry only a low or moderate risk. We anticipate future directions in this field.

    DOI： 10.1093/ijnp/pyaa097

    PubMed

    researchmap

  • Functional characterization of rare NRXN1 variants identified in autism spectrum disorders and schizophrenia Reviewed

    Kanako Ishizuka, Tomoyuki Yoshida, Takeshi Kawabata, Ayako Imai, Hisashi Mori, Hiroki Kimura, Toshiya Inada, Yuko Okahisa, Jun Egawa, Masahide Usami, Itaru Kushima, Mako Morikawa, Takashi Okada, Masashi Ikeda, Aleksic Branko, Daisuke Mori, Toshiyuki Someya, Nakao Iwata, Norio Ozaki

    Journal of Neurodevelopmental Disorders   12 ( 1 )   2020.12

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    <title>Abstract</title>
    <sec>
    <title>Background</title>
    Rare genetic variants contribute to the etiology of both autism spectrum disorder (ASD) and schizophrenia (SCZ). Most genetic studies limit their focus to likely gene-disrupting mutations because they are relatively easier to interpret their effects on the gene product. Interpretation of missense variants is also informative to some pathophysiological mechanisms of these neurodevelopmental disorders; however, their contribution has not been elucidated because of relatively small effects. Therefore, we characterized missense variants detected in <italic>NRXN1</italic>, a well-known neurodevelopmental disease-causing gene, from individuals with ASD and SCZ.


    </sec>
    <sec>
    <title>Methods</title>
    To discover rare variants with large effect size and to evaluate their role in the shared etiopathophysiology of ASD and SCZ, we sequenced <italic>NRXN1</italic> coding exons with a sample comprising 562 Japanese ASD and SCZ patients, followed by a genetic association analysis in 4273 unrelated individuals. Impact of each missense variant detected here on cell surface expression, interaction with NLGN1, and synaptogenic activity was analyzed using an in vitro functional assay and in silico three-dimensional (3D) structural modeling.


    </sec>
    <sec>
    <title>Results</title>
    Through mutation screening, we regarded three ultra-rare missense variants (T737M, D772G, and R856W), all of which affected the LNS4 domain of <italic>NRXN1</italic>α isoform<italic>,</italic> as disease-associated variants. Diagnosis of individuals with T737M, D772G, and R856W was 1ASD and 1SCZ, 1ASD, and 1SCZ, respectively. We observed the following phenotypic and functional burden caused by each variant. (i) D772G and R856W carriers had more serious social disabilities than T737M carriers. (ii) In vitro assay showed reduced cell surface expression of NRXN1α by D772G and R856W mutations. In vitro functional analysis showed decreased NRXN1α-NLGN1 interaction of T737M and D772G mutants. (iii) In silico 3D structural modeling indicated that T737M and D772G mutations could destabilize the rod-shaped structure of LNS2-LNS5 domains, and D772G and R856W could disturb N-glycan conformations for the transport signal.


    </sec>
    <sec>
    <title>Conclusions</title>
    The combined data suggest that missense variants in <italic>NRXN1</italic> could be associated with phenotypes of neurodevelopmental disorders beyond the diagnosis of ASD and/or SCZ.


    </sec>

    DOI： 10.1186/s11689-020-09325-2

    researchmap

    Other Link： http://link.springer.com/article/10.1186/s11689-020-09325-2/fulltext.html

  • Rare genetic variants in the gene encoding histone lysine demethylase 4C (KDM4C) and their contributions to susceptibility to schizophrenia and autism spectrum disorder Reviewed

    Hidekazu Kato, Itaru Kushima, Daisuke Mori, Akira Yoshimi, Branko Aleksic, Yoshihiro Nawa, Miho Toyama, Sho Furuta, Yanjie Yu, Kanako Ishizuka, Hiroki Kimura, Yuko Arioka, Keita Tsujimura, Mako Morikawa, Takashi Okada, Toshiya Inada, Masahiro Nakatochi, Keiko Shinjo, Yutaka Kondo, Kozo Kaibuchi, Yasuko Funabiki, Ryo Kimura, Toshimitsu Suzuki, Kazuhiro Yamakawa, Masashi Ikeda, Nakao Iwata, Tsutomu Takahashi, Michio Suzuki, Yuko Okahisa, Manabu Takaki, Jun Egawa, Toshiyuki Someya, Norio Ozaki

    Translational Psychiatry   10 ( 1 )   2020.12

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    <title>Abstract</title>Dysregulation of epigenetic processes involving histone methylation induces neurodevelopmental impairments and has been implicated in schizophrenia (SCZ) and autism spectrum disorder (ASD). Variants in the gene encoding lysine demethylase 4C (<italic>KDM4C</italic>) have been suggested to confer a risk for such disorders. However, rare genetic variants in <italic>KDM4C</italic> have not been fully evaluated, and the functional impact of the variants has not been studied using patient-derived cells. In this study, we conducted copy number variant (CNV) analysis in a Japanese sample set (2605 SCZ and 1141 ASD cases, and 2310 controls). We found evidence for significant associations between CNVs in <italic>KDM4C</italic> and SCZ (<italic>p</italic> = 0.003) and ASD (<italic>p</italic> = 0.04). We also observed a significant association between deletions in <italic>KDM4C</italic> and SCZ (corrected <italic>p</italic> = 0.04). Next, to explore the contribution of single nucleotide variants in <italic>KDM4C</italic>, we sequenced the coding exons in a second sample set (370 SCZ and 192 ASD cases) and detected 18 rare missense variants, including p.D160N within the JmjC domain of KDM4C. We, then, performed association analysis for p.D160N in a third sample set (1751 SCZ and 377 ASD cases, and 2276 controls), but did not find a statistical association with these disorders. Immunoblotting analysis using lymphoblastoid cell lines from a case with <italic>KDM4C</italic> deletion revealed reduced KDM4C protein expression and altered histone methylation patterns. In conclusion, this study strengthens the evidence for associations between <italic>KDM4C</italic> CNVs and these two disorders and for their potential functional effect on histone methylation patterns.

    DOI： 10.1038/s41398-020-01107-7

    researchmap

    Other Link： http://www.nature.com/articles/s41398-020-01107-7

  • Rare single-nucleotide DAB1 variants and their contribution to Schizophrenia and autism spectrum disorder susceptibility. Reviewed International journal

    Yoshihiro Nawa, Hiroki Kimura, Daisuke Mori, Hidekazu Kato, Miho Toyama, Sho Furuta, Yanjie Yu, Kanako Ishizuka, Itaru Kushima, Branko Aleksic, Yuko Arioka, Mako Morikawa, Takashi Okada, Toshiya Inada, Kozo Kaibuchi, Masashi Ikeda, Nakao Iwata, Michio Suzuki, Yuko Okahisa, Jun Egawa, Toshiyuki Someya, Fumichika Nishimura, Tsukasa Sasaki, Norio Ozaki

    Human genome variation   7 ( 1 )   37 - 37   2020.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Disabled 1 (DAB1) is an intracellular adaptor protein in the Reelin signaling pathway and plays an essential role in correct neuronal migration and layer formation in the developing brain. DAB1 has been repeatedly reported to be associated with neurodevelopmental disorders including schizophrenia (SCZ) and autism spectrum disorders (ASD) in genetic, animal, and postmortem studies. Recently, increasing attention has been given to rare single-nucleotide variants (SNVs) found by deep sequencing of candidate genes. In this study, we performed exon-targeted resequencing of DAB1 in 370 SCZ and 192 ASD patients using next-generation sequencing technology to identify rare SNVs with a minor allele frequency <1%. We detected two rare missense mutations (G382C, V129I) and then performed a genetic association study in a sample comprising 1763 SCZ, 380 ASD, and 2190 healthy control subjects. Although no statistically significant association with the detected mutations was observed for either SCZ or ASD, G382C was found only in the case group, and in silico analyses and in vitro functional assays suggested that G382C alters the function of the DAB1 protein. The rare variants of DAB1 found in the present study should be studied further to elucidate their potential functional relevance to the pathophysiology of SCZ and ASD.

    DOI： 10.1038/s41439-020-00125-7

    PubMed

    researchmap

  • Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole Reviewed

    Yoshiaki Obayashi, Satoshi Mitsui, Shinji Sakamoto, Nozomu Minao, Bunta Yoshimura, Toshiki Kono, Yuji Yada, Yuko Okahisa, Soshi Takao, Yoshiki Kishi, Toshihiko Takeda, Manabu Takaki, Norihito Yamada

    PSYCHOPHARMACOLOGY   237 ( 1 )   167 - 175   2020.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00213-019-05352-7

    Web of Science

    researchmap

  • Anti-NMDA-receptor antibody in initial diagnosis of mood disorder. Reviewed

    Kawai H, Takaki M, Sakamoto S, Shibata T, Tsuchida A, Yoshimura B, Yada Y, Matsumoto N, Sato K, Abe K, Okahisa Y, Kishi Y, Takao S, Tsutsui K, Kanbayashi T, Tanaka K, Yamada N

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology   29 ( 9 )   1041 - 1050   2019.9

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.euroneuro.2019.07.137

    PubMed

    researchmap

  • Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia and Shared Trans-Populations/Diseases Genetic Effect. Reviewed International journal

    Masashi Ikeda, Atsushi Takahashi, Yoichiro Kamatani, Yukihide Momozawa, Takeo Saito, Kenji Kondo, Ayu Shimasaki, Kohei Kawase, Takaya Sakusabe, Yoshimi Iwayama, Tomoko Toyota, Tomoyasu Wakuda, Mitsuru Kikuchi, Nobuhisa Kanahara, Hidenaga Yamamori, Yuka Yasuda, Yuichiro Watanabe, Satoshi Hoya, Branko Aleksic, Itaru Kushima, Heii Arai, Manabu Takaki, Kotaro Hattori, Hiroshi Kunugi, Yuko Okahisa, Tohru Ohnuma, Norio Ozaki, Toshiyuki Someya, Ryota Hashimoto, Takeo Yoshikawa, Michiaki Kubo, Nakao Iwata

    Schizophrenia bulletin   45 ( 4 )   824 - 834   2019.6

    　More details

    Language：English  

    Genome-wide association studies (GWASs) have identified >100 susceptibility loci for schizophrenia (SCZ) and demonstrated that SCZ is a polygenic disorder determined by numerous genetic variants but with small effect size. We conducted a GWAS in the Japanese (JPN) population (a) to detect novel SCZ-susceptibility genes and (b) to examine the shared genetic risk of SCZ across (East Asian [EAS] and European [EUR]) populations and/or that of trans-diseases (SCZ, bipolar disorder [BD], and major depressive disorder [MDD]) within EAS and between EAS and EUR (trans-diseases/populations). Among the discovery GWAS subjects (JPN-SCZ GWAS: 1940 SCZ cases and 7408 controls) and replication dataset (4071 SCZ cases and 54479 controls), both comprising JPN populations, 3 novel susceptibility loci for SCZ were identified: SPHKAP (Pbest = 4.1 × 10-10), SLC38A3 (Pbest = 5.7 × 10-10), and CABP1-ACADS (Pbest = 9.8 × 10-9). Subsequent meta-analysis between our samples and those of the Psychiatric GWAS Consortium (PGC; EUR samples) and another study detected 12 additional susceptibility loci. Polygenic risk score (PRS) prediction revealed a shared genetic risk of SCZ across populations (Pbest = 4.0 × 10-11) and between SCZ and BD in the JPN population (P ~ 10-40); however, a lower variance-explained was noted between JPN-SCZ GWAS and PGC-BD or MDD within/across populations. Genetic correlation analysis supported the PRS results; the genetic correlation between JPN-SCZ and PGC-SCZ was ρ = 0.58, whereas a similar/lower correlation was observed between the trans-diseases (JPN-SCZ vs JPN-BD/EAS-MDD, rg = 0.56/0.29) or trans-diseases/populations (JPN-SCZ vs PGC-BD/MDD, ρ = 0.38/0.12). In conclusion, (a) Fifteen novel loci are possible susceptibility genes for SCZ and (b) SCZ "risk" effect is shared with other psychiatric disorders even across populations.

    DOI： 10.1093/schbul/sby140

    PubMed

    researchmap

  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis in Psychiatry. Reviewed

    Sakamoto S, Kawai H, Okahisa Y, Tsutsui K, Kanbayashi T, Tanaka K, Mizuki Y, Takaki M, Yamada N

    Acta medica Okayama   73 ( 3 )   189 - 195   2019.6

    　More details

  • Assessment of a glyoxalase I frameshift variant, p.P122fs, in Japanese patients with schizophrenia. Reviewed International journal

    Kanako Ishizuka, Hiroki Kimura, Itaru Kushima, Toshiya Inada, Yuko Okahisa, Masashi Ikeda, Nakao Iwata, Daisuke Mori, Branko Aleksic, Norio Ozaki

    Psychiatric genetics   28 ( 5 )   90 - 93   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Enhanced carbonyl stress has been observed in a subgroup of patients with schizophrenia. Glyoxalase I, which is encoded by GLO1, is an enzyme that protects against carbonyl stress. In this study, we focused on the association between rare genetic variants of GLO1 and schizophrenia. First, we identified one heterozygous frameshift variant, p.P122fs, in 370 Japanese schizophrenia cases with allele frequencies of up to 1% by exon-targeted mutation screening of GLO1. We then performed an association analysis on 1282 cases and 1764 controls with this variant. The variant was found in three cases and eight controls. There was no statistically significant association between p.P122fs in GLO1 and schizophrenia (P=0.25). This frameshift variant in GLO1 might occur at near-polymorphic frequencies in the Japanese population, although further investigations using larger samples and biological analyses are needed to exclude the possibility of a low-penetrance genetic risk associated with this variant.

    DOI： 10.1097/YPG.0000000000000204

    PubMed

    researchmap

  • Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine Reviewed

    Manabu Takaki, Masafumi Kodama, Yutaka Mizuki, Hiroki Kawai, Bunta Yoshimura, Makiko Kishimoto, Shinji Sakamoto, Yuko Okahisa, Norihito Yamada

    European Neuropsychopharmacology   28 ( 5 )   610 - 619   2018.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier B.V.  

    DOI： 10.1016/j.euroneuro.2018.03.004

    Scopus

    PubMed

    researchmap

  • Rare loss of function mutations in N-methyl-D-aspartate glutamate receptors and their contributions to schizophrenia susceptibility. Reviewed International journal

    Yanjie Yu, Yingni Lin, Yuto Takasaki, Chenyao Wang, Hiroki Kimura, Jingrui Xing, Kanako Ishizuka, Miho Toyama, Itaru Kushima, Daisuke Mori, Yuko Arioka, Yota Uno, Tomoko Shiino, Yukako Nakamura, Takashi Okada, Mako Morikawa, Masashi Ikeda, Nakao Iwata, Yuko Okahisa, Manabu Takaki, Shinji Sakamoto, Toshiyuki Someya, Jun Egawa, Masahide Usami, Masaki Kodaira, Akira Yoshimi, Tomoko Oya-Ito, Branko Aleksic, Kinji Ohno, Norio Ozaki

    Translational psychiatry   8 ( 1 )   12 - 12   2018.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    In schizophrenia (SCZ) and autism spectrum disorder (ASD), the dysregulation of glutamate transmission through N-methyl-D-aspartate receptors (NMDARs) has been implicated as a potential etiological mechanism. Previous studies have accumulated evidence supporting NMDAR-encoding genes' role in etiology of SCZ and ASD. We performed a screening study for exonic regions of GRIN1, GRIN2A, GRIN2C, GRIN2D, GRIN3A, and GRIN3B, which encode NMDAR subunits, in 562 participates (370 SCZ and 192 ASD). Forty rare variants were identified including 38 missense, 1 frameshift mutation in GRIN2C and 1 splice site mutation in GRIN2D. We conducted in silico analysis for all variants and detected seven missense variants with deleterious prediction. De novo analysis was conducted if pedigree samples were available. The splice site mutation in GRIN2D is predicted to result in intron retention by minigene assay. Furthermore, the frameshift mutation in GRIN2C and splice site mutation in GRIN2D were genotyped in an independent sample set comprising 1877 SCZ cases, 382 ASD cases, and 2040 controls. Both of them were revealed to be singleton. Our study gives evidence in support of the view that ultra-rare variants with loss of function (frameshift, nonsense or splice site) in NMDARs genes may contribute to possible risk of SCZ.

    DOI： 10.1038/s41398-017-0061-y

    PubMed

    researchmap

  • EXPRESSION PROFILES AND COGNITIVE FUNCTION AS A PREDICTIVE BIOMARKER OF SCHIZOPHRENIA: A PILOT STUDY Reviewed

    Yuko Okahisa, Shinji Sakamoto, Manabu Takaki, Norihito Yamada

    EUROPEAN NEUROPSYCHOPHARMACOLOGY   27   S261 - S261   2017.10

    　More details

    Language：English  

    Web of Science

    researchmap

  • Estimated cognitive decline in patients with schizophrenia: A multicenter study Reviewed

    Haruo Fujino, Chika Sumiyoshi, Yuka Yasuda, Hidenaga Yamamori, Michiko Fujimoto, Masaki Fukunaga, Kenichiro Miura, Yuto Takebayashi, Naohiro Okada, Shuichi Isomura, Naoko Kawano, Atsuhito Toyomaki, Hironori Kuga, Masanori Isobe, Kazuto Oya, Yuko Okahisa, Manabu Takaki, Naoki Hashimoto, Masaki Kato, Toshiaki Onitsuka, Takefumi Ueno, Tohru Ohnuma, Kiyoto Kasai, Norio Ozaki, Tomiki Sumiyoshi, Osamu Imura, Ryota Hashimoto

    PSYCHIATRY AND CLINICAL NEUROSCIENCES   71 ( 5 )   294 - 300   2017.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/pcn.12474

    Web of Science

    PubMed

    researchmap

  • Human Rho Guanine Nucleotide Exchange Factor 11 (ARHGEF11) Regulates Dendritic Morphogenesis Reviewed

    Yutaka Mizuki, Manabu Takaki, Shinji Sakamoto, Sojiro Okamoto, Makiko Kishimoto, Yuko Okahisa, Masahiko Itoh, Norihito Yamada

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   18 ( 1 )   2017.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3390/ijms18010067

    Web of Science

    PubMed

    researchmap

  • A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder Reviewed

    Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N, Sasaki T, Ohmori T, Okamoto Y, Kawasaki H, Shimodera S, Kato T, Yoneda H, Yoshimura R, Iyo M, Matsuda K, Akiyama M, Ashikawa K, Kashiwase K, Tokunaga K, Kondo K, Saito T, Shimasaki A, Kawase K, Kitajima T, Matsuo K, Itokawa M, Someya T, Inada T, Hashimoto R, Inoue T, Akiyama K, Tanii H, Arai H, Kanba S, Ozaki N, Kusumi I, Yoshikawa T, Kubo M, Iwata N

    Mol Psychiatry   23 ( 3 )   639 - 647   2017

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1038/mp.2016.259

    researchmap

    Other Link： http://orcid.org/0000-0001-7856-3952

  • Expression Profiles and Neurocognitive/Social Functions as a Predictive Biomarker of Schizophrenia Reviewed

    Okahisa Yuko, Sakamoto Shinji, Kishimoto Makiko, Takaki Manabu, Yamada Norihito

    EARLY INTERVENTION IN PSYCHIATRY   10   153   2016.10

    　More details

  • The Relationship Between Development of Neuronal and Astrocytic Tau Pathologies in Subcortical Nuclei and Progression of Argyrophilic Grain Disease Reviewed

    Chikako Ikeda, Osamu Yokota, Shigeto Nagao, Hideki Ishizu, Etsuko Oshima, Masato Hasegawa, Yuko Okahisa, Seishi Terada, Norihito Yamada

    BRAIN PATHOLOGY   26 ( 4 )   488 - 505   2016.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/bpa.12319

    Web of Science

    PubMed

    researchmap

  • Individual risk alleles of susceptibility to schizophrenia are associated with poor clinical and social outcomes Reviewed

    Shinji Sakamoto, Manabu Takaki, Yuko Okahisa, Yutaka Mizuki, Masatoshi Inagaki, Hiroshi Ujike, Toshiharu Mitsuhashi, Soshi Takao, Masashi Ikeda, Yosuke Uchitomi, Nakao Iwata, Norihito Yamada

    JOURNAL OF HUMAN GENETICS   61 ( 4 )   329 - 334   2016.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/jhg.2015.153

    Web of Science

    PubMed

    researchmap

  • Factors predicting work outcome in Japanese patients with schizophrenia: Role of multiple functioning levels Reviewed

    Chika Sumiyoshi, Philip D. Harvey, Manabu Takaki, Yuko Okahisa, Taku Sato, Ichiro Sora, Keith H. Nuechterlein, Kenneth L. Subotnik, Tomiki Sumiyoshi

    Schizophrenia Research: Cognition   2 ( 3 )   105 - 112   2015.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier Inc.  

    DOI： 10.1016/j.scog.2015.07.003

    Scopus

    PubMed

    researchmap

  • A genome-wide association study of late-onset Alzheimer's disease in a Japanese population Reviewed

    Atsushi Hirano, Tomoyuki Ohara, Atsushi Takahashi, Masayuki Aoki, Yuta Fuyuno, Kyota Ashikawa, Takashi Morihara, Masatoshi Takeda, Kouzin Kamino, Etsuko Oshima, Yuko Okahisa, Nobuto Shibata, Heii Arai, Hiroyasu Akatsu, Masashi Ikeda, Nakao Iwata, Toshiharu Ninomiya, Akira Monji, Takanari Kitazono, Yutaka Kiyohara, Michiaki Kubo, Shigenobu Kanba

    PSYCHIATRIC GENETICS   25 ( 4 )   139 - 146   2015.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/YPG.0000000000000090

    Web of Science

    PubMed

    researchmap

  • Difference in determinants of caregiver burden between amnestic mild cognitive impairment and mild Alzheimer's disease Reviewed

    Chikako Ikeda, Seishi Terada, Etsuko Oshima, Satoshi Hayashi, Yuko Okahisa, Manabu Takaki, Masatoshi Inagaki, Osamu Yokota, Yosuke Uchitomi

    PSYCHIATRY RESEARCH   226 ( 1 )   242 - 246   2015.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.psychres.2014.12.055

    Web of Science

    PubMed

    researchmap

  • Human Rho guanine nucleotide exchange factor 11 gene is associated with schizophrenia in a Japanese population Reviewed

    Yutaka Mizuki, Manabu Takaki, Yuko Okahisa, Shinji Sakamoto, Masafumi Kodama, Hiroshi Ujike, Yosuke Uchitomi

    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL   29 ( 6 )   552 - 558   2014.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/hup.2435

    Web of Science

    PubMed

    researchmap

  • Four polymorphisms of the pericentriolar material 1 (PCM1) gene are not associated with schizophrenia in a Japanese population Reviewed

    Shinji Sakamoto, Manabu Takaki, Yuko Okahisa, Yutaka Mizuki, Masafumi Kodama, Hiroshi Ujike, Yosuke Uchitomi

    PSYCHIATRY RESEARCH   216 ( 2 )   288 - 289   2014.5

    　More details

  • 非鎮静系抗精神病薬aripiprazole、blonanserinの適応外使用の状況と理由の検討

    高木 学, 北川 航平, 江角 悟, 水木 寛, 酒本 真次, 藤原 雅樹, 岡久 祐子, 井上 真一郎, 児玉 匡史, 岡部 伸幸, 寺田 整司, 内富 庸介

    臨床精神薬理   17 ( 3 )   375 - 388   2014.3

    　More details

    Language：Japanese   Publisher：(株)星和書店  

    researchmap

  • Utility of the UCSD Performance-based Skills Assessment-Brief Japanese version: Discriminative ability and relation to neurocognition Reviewed

    Chika Sumiyoshi, Manbu Takaki, Yuko Okahisa, Thomas L. Patterson, Philip D. Harvey, Tomiki Sumiyoshi

    Schizophrenia Research: Cognition   1 ( 3 )   137 - 143   2014

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier Inc.  

    DOI： 10.1016/j.scog.2014.08.002

    Scopus

    PubMed

    researchmap

  • Evidence for Shared Genetic Risk Between Methamphetamine-Induced Psychosis and Schizophrenia Reviewed

    Masashi Ikeda, Yuko Okahisa, Branko Aleksic, Mujun Won, Naoki Kondo, Nobuya Naruse, Kumi Aoyama-Uehara, Ichiro Sora, Masaomi Iyo, Ryota Hashimoto, Yoshiya Kawamura, Nao Nishida, Taku Miyagawa, Masatoshi Takeda, Tsukasa Sasaki, Katsushi Tokunaga, Norio Ozaki, Hiroshi Ujike, Nakao Iwata

    NEUROPSYCHOPHARMACOLOGY   38 ( 10 )   1864 - 1870   2013.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/npp.2013.94

    Web of Science

    PubMed

    researchmap

  • MATRICSコンセンサス認知機能評価バッテリー日本語版の計量心理学的特性

    兼田 康宏, 大森 哲郎, 岡久 祐子, 住吉 太幹, 朴 盛弘, 上岡 義典, 高木 学, 西山 志満子, 中込 和幸, Ichiro Sora

    精神神経学雑誌   ( 2013特別 )   S - 629   2013.5

    　More details

    Language：Japanese  

    researchmap

  • Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery: Validation of the Japanese version Reviewed

    Yasuhiro Kaneda, Tetsuro Ohmori, Yuko Okahisa, Tomiki Sumiyoshi, Shenghong Pu, Yoshinori Ueoka, Manabu Takaki, Kazuyuki Nakagome, Ichiro Sora

    PSYCHIATRY AND CLINICAL NEUROSCIENCES   67 ( 3 )   182 - 188   2013.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/pcn.12029

    Web of Science

    PubMed

    researchmap

  • Adjunctive yokukansan treatment improved cognitive functions in a patient with schizophrenia Reviewed

    Shinji Sakamoto, Hiroshi Ujike, Manabu Takaki, Yutaka Mizuki, Yuko Okahisa, Masafumi Kodama, Yosuke Uchitomi

    Journal of Neuropsychiatry and Clinical Neurosciences   25 ( 3 )   E39 - E40   2013

    　More details

  • Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia Reviewed

    Manabu Takaki, Yuko Okahisa, Masafumi Kodama, Yutaka Mizuki, Shinji Sakamoto, Hiroshi Ujike, Yosuke Uchitomi

    ACTA NEUROPSYCHIATRICA   24 ( 6 )   380 - 383   2012.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/j.1601-5215.2012.00663.x

    Web of Science

    PubMed

    researchmap

  • Association Study of Two Cannabinoid Receptor Genes, CNR1 and CNR2, with Methamphetamine Dependence. Reviewed International journal

    Okahisa Y, Kodama M, Takaki M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Ujike H

    Curr Neuropharmacol   9 ( 1 )   183 - 189   2011.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Several studies have suggested that the endocannabinoid system plays significant roles in the vulnerability to psychiatric disorders including drug abuse. To examine the possible association of the CNR1 and CNR2 genes, which encode cannabinoid receptors CB1 and CB2, with methamphetamine dependence, we investigated three single nucleotide polymorphisms (SNPs) (rs806379, rs1535255, rs2023239) in intron 2 of the CNR1 gene and a nonsynonymous SNP, Q63R, in the CNR2 gene. The study samples consisted of 223 patients with methamphetamine dependence and 292 age- and sex- matched controls. There were no significant differences between the patients and controls in genotypic or allelic distribution of any SNP of the CNR1 and CNR2 genes. We also analyzed the clinical features of methamphetamine dependence. Rs806379 of the CNR1 gene showed a significant association with the phenotype of latency of psychosis after the first consumption of methamphetamine. Patients with the T allele or T-positive genotypes (T/T or A/T) may develop a rapid onset of psychosis after methamphetamine abuse. The present study suggests a possibility that genetic variants of the CNR1 gene may produce a liability to the complication of psychotic state after abuse of methamphetamine; however, our findings need to be confirmed by future replications.

    DOI： 10.2174/157015911795017191

    PubMed

    researchmap

  • Association study of serine racemase gene with methamphetamine psychosis. Reviewed International journal

    Yokobayashi E, Ujike H, Kotaka T, Okahisa Y, Takaki M, Kodama M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S

    Curr Neuropharmacol   9 ( 1 )   169 - 175   2011.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Experimental studies have demonstrated that not only dopaminergic signaling but also glutamatergic/NMDA receptor signaling play indispensable roles in the development of methamphetamine psychosis. Our recent genetic studies provided evidence that genetic variants of glutamate-related genes such as DTNBP1, GLYT1, and G72, which are involved in glutamate release and regulation of co-agonists for NMDA receptors, conferred susceptibility to methamphetamine psychosis. Serine racemase converts l-serine to d-serine, which is an endogenous co-agonist for NMDA receptors. Three single nucleotide polymorphisms (SNPs) in the promoter region of the serine racemase gene (SRR), rs224770, rs3760229, and rs408067, were proven to affect the transcription activity of SRR. Therefore, we examined these SNPs in 225 patients with methamphetamine psychosis and 291 age- and sex-matched controls. There was no significant association between methamphetamine psychosis and any SNP examined or between the disorder and haplotypes comprising the three SNPs. However, rs408067 was significantly associated with the prognosis for methamphetamine psychosis and multi-substance abuse status. The patients with C-positive genotypes (CC or CG) of rs408067 showed better prognosis of psychosis after therapy and less abuse of multiple substances than the patients with GG genotypes. Because the C allele of rs408067 reduces the expression of SRR, a lower d-serine level or reduced NMDA receptor activation may affect the prognosis of methamphetamine psychosis and multiple substance abuse. Our sample size is, however, not large enough to eliminate the possibility of a type I error, our findings must be confirmed by replicate studies with larger samples.

    DOI： 10.2174/157015911795017092

    PubMed

    researchmap

  • Association Between 5HT1b Receptor Gene and Methamphetamine Dependence. Reviewed International journal

    Ujike H, Kishimoto M, Okahisa Y, Kodama M, Takaki M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N

    Curr Neuropharmacol   9 ( 1 )   163 - 168   2011.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Several lines of evidence implicate serotonergic dysfunction in diverse psychiatric disorders including anxiety, depression, and drug abuse. Mice with a knock-out of the 5HT1b receptor gene (HTR1B) displayed increased locomotor response to cocaine and elevated motivation to self-administer cocaine and alcohol. Previous genetic studies showed significant associations of HTR1B with alcohol dependence and substance abuse, but were followed by inconsistent results. We examined a case-control genetic association study of HTR1B with methamphetamine-dependence patients in a Japanese population. The subjects were 231 patients with methamphetamine dependence, 214 of whom had a co-morbidity of methamphetamine psychosis, and 248 age- and sex-matched healthy controls. The three single nucleotide polymorphisms (SNPs), rs130058 (A-165T), rs1228814 (A-700C) and rs1228814 (A+1180G) of HTR1B were genotyped. There was no significant difference in allelic and genotypic distributions of the SNPs between methamphetamine dependence and the control. Genetic associations of HTR1B were tested with several clinical phenotypes of methamphetamine dependence and/or psychosis, such as age at first abuse, duration of latency from the first abuse to onset of psychosis, prognosis of psychosis after therapy, and complication of spontaneous relapse of psychotic state. There was, however, no asscocation between any SNP and the clinical phenotypes. Haplotype analyses showed the three SNPs examined were within linkage disequilibrium, which implied that the three SNPs covered the whole HTR1B, and distribution of estimated haplotype frequency was not different between the groups. The present findings may indicate that HTR1B does not play a major role in individual susceptibility to methamphetamine dependence or development of methamphetamine-induced psychosis.

    DOI： 10.2174/157015911795017137

    PubMed

    researchmap

  • Association between the Regulator of G-protein Signaling 9 Gene and Patients with Methamphetamine Use Disorder and Schizophrenia. Reviewed International journal

    Okahisa Y, Kodama M, Takaki M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Ujike H

    Curr Neuropharmacol   9 ( 1 )   190 - 194   2011.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The regulator of G-protein signaling (RGS) modulates the functioning of heterotrimeric G protein. RGS9-2 is highly expressed in the striatum and plays a role in modulating dopaminergic receptor-mediated signaling cascades. Previous studies suggested that the RGS9 gene might contribute to the susceptibility to psychotic diseases. Therefore, we investigated the association between the RGS9 gene and two related dopamine psychoses, schizophrenia and methamphetamine use disorders. The subjects comprised 487 patients of schizophrenia and 464 age- and sex-matched healthy controls and 220 patients of methamphetamine use disorder and 289 controls. We genotyped two nonsynonymous polymorphisms, rs12452285 (Leu225Ser) and rs34797451 (His498Arg), of the RGS9 gene. Rs34797451 showed monomorphism in the present Japanese population, but rs12452285 showed polymorphism. There were no significant differences in genotypic or allelic distributions of rs12452285 between patients with schizophrenia and the corresponding control or between patients with methamphetamine use disorder and the corresponding control. We also analyzed the clinical features of methamphetamine use disorder. We found a significant association in allelic distribution with the phenotypes of age at first consumption (p=0.047). The present study suggested that the RGS9 gene is unlikely to play a major role in schizophrenia and methamphetamine dependence liability and/or the development of methamphetamine induced psychosis, at least in a Japanese population.

    DOI： 10.2174/157015911795017029

    PubMed

    researchmap

  • [Overview of genetics and substance use disorders]. Reviewed

    Takaki M, Okahisa Y, Ujike H

    Nihon rinsho. Japanese journal of clinical medicine   68 ( 8 )   1451 - 1456   2010.8

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    A genetic component in etiology of substance dependence is very large, and the estimated hereditary rates by twin and family studies are 70% or more. Extensive classical linkage analyses for alcohol and substance dependence revealed numerous but weak susceptibility loci on every chromosomes. Genetic association studies including whole genome examination showed many shared genomic risks for substance dependence of diverse classes, e.g., alcohol, nicotine, opioids, cocaine, amphetamines and cannabinoids. In contrast, some specific genetic risks or protective factors for individual drug are also found. This paper reviews the current status of research into the genetics of substance dependence.

    PubMed

    researchmap

  • Leukemia inhibitory factor gene is associated with schizophrenia and working memory function Reviewed

    Yuko Okahisa, Hiroshi Ujike, Hiroshi Kunugi, Takeshi Ishihara, Masafumi Kodama, Manabu Takaki, Tatsuya Kotaka, Shigetoshi Kuroda

    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY   34 ( 1 )   172 - 176   2010.2

    　More details

  • Association study of gender identity disorder and sex hormone-related genes Reviewed

    Hiroshi Ujike, Kyohei Otani, Mikiya Nakatsuka, Kazushi Ishii, Aiko Sasaki, Tomoko Oishi, Toshiki Sato, Yuko Okahisa, Yosuke Matsumoto, Yuzaburo Namba, Yoshihiro Kimata, Shigetoshi Kuroda

    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY   33 ( 7 )   1241 - 1244   2009.10

    　More details

  • G72 gene is associated with susceptibility to methamphetamine psychosis Reviewed

    Tatsuya Kotaka, Hiroshi Ujike, Yuko Okahisa, Manabu Takaki, Kenji Nakata, Masafumi Kodama, Toshiya Inada, Mitsuhiko Yamada, Naohisa Uchimura, Nakao Iwata, Ichiro Sora, Masaomi Iyo, Norio Ozaki, Shigetoshi Kuroda

    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY   33 ( 6 )   1046 - 1049   2009.8

    　More details

  • Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis Reviewed

    Hiroshi Ujike, Takeshi Katsu, Yuko Okahisa, Manabu Takaki, Masafumi Kodama, Toshiya Inada, Naohisa Uchimura, Mitsuhiko Yamada, Nakao Iwata, Ichiro Sora, Masaomi Iyo, Norio Ozaki, Shigetoshi Kuroda

    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY   33 ( 4 )   625 - 629   2009.6

    　More details

  • Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence Reviewed

    Yuko Okahisa, Hiroshi Ujike, Tatsuya Kotaka, Yukitaka Morita, Masafumi Kodama, Toshiya Inada, Mitsuhiko Yamada, Nakao Iwata, Masaomi Iyo, Ichiro Sora, Norio Ozaki, Shigetoshi Kuroda

    PSYCHIATRY AND CLINICAL NEUROSCIENCES   63 ( 3 )   417 - 422   2009

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/j.1440-1819.2009.01961.x

    Web of Science

    PubMed

    researchmap

  • Association study between casein kinase 1 epsilon gene and methamphetamine dependence. Reviewed International journal

    Kotaka T, Ujike H, Morita Y, Kishimoto M, Okahisa Y, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S

    Ann N Y Acad Sci   1139   43 - 48   2008.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Casein kinase 1 epsilon (CKIepsilon) is a component of the DARPP-32 in second-messenger pathway. CKIepsilon phosphorylates and activates DARPP-32, a key molecule in various complex signaling pathways, including dopamine and glutamine signaling, which have both been demonstrated to be main pathways in substance dependence. A recent clinical study showed that rs135745, a noncoding single nucleotide polymorphism of the 3'-untranslated region of the CSNK1E gene, was associated with the intensity of the subjective response to an oral amphetamine dose in normal volunteers. Differences in sensitivity to the drug should affect development of dependence to it. Hence, we genotyped rs135745 of the CSNK1E (MIM 600863) gene in 215 patients with methamphetamine dependence and 274 age- and gender-matched normal controls. No significant differences in genotype and allele frequencies were observed between the patients with methamphetamine dependence and controls. There was also no significant association between rs135745 and the clinical characteristics of methamphetamine dependence and co-morbid methamphetamine psychosis (e.g., age of first consumption, latency of psychosis, prognosis of psychosis after therapy, spontaneous relapse of psychotic symptoms, and poly-substance abuse status). The present findings suggest that having a genetic variant of the CSNK1E gene did not affect susceptibility to methamphetamine dependence or psychosis, at least in a Japanese population.

    DOI： 10.1196/annals.1432.025

    PubMed

    researchmap

  • Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: A cohort study Reviewed

    Hiroshi Ujike, Akira Nomura, Yukitaka Morita, Akiko Morio, Yuko Okahisa, Tatsuya Kotaka, Masafumi Kodama, Takeshi Ishihara, Shigetoshi Kuroda

    JOURNAL OF CLINICAL PSYCHIATRY   69 ( 9 )   1416 - 1422   2008.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

    PubMed

    researchmap

  • The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population Reviewed

    Makiko Kishimoto, Hiroshi Ujike, Yuko Okahisa, Tatsuya Kotaka, Manabu Takaki, Masafumi Kodama, Toshiya Inada, Mitsuhiko Yamada, Naohisa Uchimura, Nakao Iwata, Ichiro Sora, Masaomi Iyo, Norio Ozaki, Shigetoshi Kuroda

    BEHAVIORAL AND BRAIN FUNCTIONS   4   37   2008.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/1744-9081-4-37

    Web of Science

    PubMed

    researchmap

  • Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence Reviewed

    Kyohei Otani, Hiroshi Ujike, Ayumu Sakai, Yuko Okahisa, Tatsuya Kotaka, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Toru Hori, Mitsuhiko Yamada, Yoshimoto Sekine, Nakao Iwata, Masaomi Iyo, Ichiro Sora, Norio Ozaki, Shigetoshi Kuroda

    NEUROSCIENCE LETTERS   434 ( 1 )   88 - 92   2008.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.neulet.2008.01.033

    Web of Science

    PubMed

    researchmap

  • The Glycine Transporter 1 Gene (GLYT1) Is Associated With Methamphetamine-Use Disorder Reviewed

    Yukitaka Morita, Hiroshi Ujike, Yuji Tanaka, Makiko Kishimoto, Yuko Okahisa, Tatsuya Kotaka, Mutsuo Harano, Toshiya Inada, Tokutaro Komiyama, Toru Hori, Mitsuhiko Yamada, Yoshimoto Sekine, Nakao Iwata, Masaomi Iyo, Ichiro Sora, Norio Ozaki, Shigetoshi Kuroda

    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS   147B ( 1 )   54 - 58   2008.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/ajmg.b.30565

    Web of Science

    PubMed

    researchmap

  • The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis Reviewed

    Makiko Kishimoto, Hiroshi Ujike, Yasuko Motohashi, Yuji Tanaka, Yuko Kahisa, Tatsuya Kotaka, Mutsuo Harano, Toshiya Inada, Mitsuhiko Yamada, Tokutaro Komiyama, Toru Hori, Yoshimoto Sekine, Nakao Iwata, Ichiro Sora, Masaomi Iyo, Norio Ozaki, Shigetoshi Kuroda

    BIOLOGICAL PSYCHIATRY   63 ( 2 )   191 - 196   2008.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.biopsych.2007.03.019

    Web of Science

    PubMed

    researchmap

  • A genetic variant of the serine racemase gene is associated with schizophrenia Reviewed

    Yukitaka Morita, Hiroshi Ujike, Yuji Tanaka, Kyohei Otani, Makiko Kishimoto, Akiko Morio, Tatsuya Kotaka, Yuko Okahisa, Masayuki Matsushita, Akiko Morikawa, Kenji Hamase, Kiyoshi Zaitsu, Shigetoshi Kuroda

    BIOLOGICAL PSYCHIATRY   61 ( 10 )   1200 - 1203   2007.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.biopsych.2006.07.025

    Web of Science

    PubMed

    researchmap

  • Association study of the dihydropyrimidinase-related protein 2 gene and methamphetamine psychosis. Reviewed International journal

    Ujike H, Sakai A, Nakata K, Tanaka Y, Kodaka T, Okahisa Y, Harano M, Inada T, Yamada M, Komiyama T, Hori T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S

    Ann N Y Acad Sci   1074   90 - 96   2006.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Dihydropyrimidinase-related protein 2 (DRP-2 or DPYSL-2)mediates the intracellular response to collapsin, a repulsive extracellular guidance cue or axonal outgrowth. DRP-2 is also referred to as collapsin response mediator protein 2 (CRMP-2). We have previously demonstrated that the DRP-2 gene is associated with susceptibility to schizophrenia, but not to bipolar disorders. In addition, a genetic association was observed with paranoid-type schizophrenia, but not with hebephrenic-type schizophrenia. It has been well documented that repeated abuse of methamphetamine (METH) for a long period frequently produces psychotic symptoms, such as auditory hallucinations and delusions that are hardly distinguishable from those of paranoid-type schizophrenia. Therefore, we hypothesized that a certain genetic variant of the DRP-2 gene may affect individual vulnerability to the development of METH-induced psychosis. We examined the genetic association by a case-control method. The polymorphism *2236T>C in the 3' untranslated region of the DRP-2 gene, which has been shown to be a negative genetic risk factor for paranoid-type schizophrenia, was analyzed in 198 patients with METH psychosis and 221 corresponding healthy controls in a Japanese population. No significant association of the DRP-2 gene with METH psychosis was found. Neither did we find an association with the clinical phenotype of METH psychosis, such as the age of first consumption of METH, latency to development of psychosis after METH abuse, prognosis of psychosis after detoxification from METH use, complication of spontaneous relapse of psychosis without reconsumption of the drug, or multisubstance abuse status. These findings indicate that a genetic variant of the DRP-2 gene may not affect the risk of METH psychosis or any clinical phenotype of the disorder.

    DOI： 10.1196/annals.1369.008

    PubMed

    researchmap

▼display all

MISC

  • 【さまざまな治療アプローチをどのように使い分けるか】統合失調症における抗精神病薬の使い分け

    高木 学, 矢田 勇慈, 酒本 真次, 岡久 祐子, 児玉 匡史, 来住 由樹, 武田 俊彦, 山田 了士

    精神科   40 ( 3 )   283 - 290   2022.3

    　More details

    Language：Japanese   Publisher：(有)科学評論社  

    researchmap

  • 抗体介在性自己免疫性脳炎と精神疾患 自己免疫性精神病 発症機序と多彩な精神症状

    高木 学, 酒本 真次, 岡久 祐子, 山田 了士

    精神神経学雑誌   ( 2021特別号 )   S294 - S294   2021.9

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 【NMDA受容体と精神疾患】精神疾患の病因における抗NMDA受容体抗体

    高木 学, 酒本 真次, 岡久 祐子, 山田 了士

    医学のあゆみ   277 ( 11 )   964 - 969   2021.6

    　More details

  • 神経免疫学と精神医学の狭間で 自己抗体を通した精神疾患のディメンショナルアプローチ

    高木 学, 河合 弘樹, 樋之津 健二, 酒本 真次, 岡久 祐子, 山田 了士

    精神神経学雑誌   ( 2020特別号 )   S358 - S358   2020.9

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 初期診断が気分障害であった患者における抗NMDA受容体抗体保有率の検討

    河合 弘樹, 高木 学, 酒本 真次, 土田 彩加, 吉村 文太, 矢田 勇慈, 岡久 祐子, 来住 由樹, 筒井 幸, 神林 崇, 田中 惠子, 山田 了士

    精神神経学雑誌   ( 2020特別号 )   S429 - S429   2020.9

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 慢性統合失調症患者におけるアリピプラゾール単剤治療への切替方法についての検討(多施設コホート研究)

    大林 芳明, 光井 聡, 酒本 真次, 皆尾 望, 吉村 文太, 耕野 敏樹, 矢田 勇慈, 岡久 祐子, 高尾 総司, 来住 由樹, 武田 俊彦, 高木 学, 山田 了士

    精神神経学雑誌   ( 2020特別号 )   S426 - S426   2020.9

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 非定型精神病患者における抗NMDA受容体抗体の陽性率の検討

    樋之津 健二, 高木 学, 河合 弘樹, 酒本 真次, 岡久 祐子, 山田 了士

    日本神経精神薬理学会年会・日本生物学的精神医学会年会・日本精神薬学会総会・学術集会合同年会プログラム・抄録集   50回・42回・4回   186 - 186   2020.8

    　More details

    Language：Japanese   Publisher：日本神経精神薬理学会・日本生物学的精神医学会・日本精神薬学会  

    researchmap

  • パーキンソン病あるいはレビー小体型認知症に伴う精神症状に対してECTを行った9例

    藤井 裕美子, 山田 裕士, 藤原 雅樹, 流王 雄太, 岡久 祐子, 酒本 真次, 山田 了士

    総合病院精神医学   31 ( Suppl. )   S - 151   2019.11

    　More details

    Language：Japanese   Publisher：(一社)日本総合病院精神医学会  

    researchmap

  • 【精神科で見落とされやすい身体疾患】自己免疫性脳炎・脳症と精神症状

    山田 了士, 高木 学, 岡久 祐子, 酒本 真次

    精神科治療学   34 ( 11 )   1239 - 1245   2019.11

    　More details

    Language：Japanese   Publisher：(株)星和書店  

    researchmap

  • Genome-wide association study detected novel susceptibility genes for schizophrenia and shared trans-populations/diseases genetic effect(和訳中)

    池田 匡志, 高橋 篤, 鎌谷 洋一郎, 桃沢 幸秀, 齋藤 竹生, 近藤 健治, 島崎 愛夕, 川瀬 康平, 作佐部 太也, 岩山 佳美, 豊田 倫子, 和久田 智靖, 菊池 充, 金原 信久, 山森 英長, 安田 由華, 渡部 雄一郎, 保谷 智史, アレクシッチ ブランコ, 久島 周, 新井 平伊, 高木 学, 服部 功太郎, 功刀 浩, 岡久 祐子, 大沼 徹, 尾崎 紀夫, 染矢 俊幸, 橋本 亮太, 吉川 武男, 久保 充明, 岩田 仲生

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   29回・49回   124 - 124   2019.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    researchmap

  • 精神疾患における抗NMDA受容体抗体保有率の検討

    酒本 真次, 河合 弘樹, 岸本 真希子, 岡久 祐子, 高木 学, 筒井 幸, 神林 崇, 田中 惠子, 山田 了士

    精神神経学雑誌   ( 2018特別号 )   S648 - S648   2018.6

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • アウトリーチ支援の導入により自宅療養が可能になった統合失調症急性増悪の1例

    植田真司, 植田真司, 岡久祐子, 川田清宏, 藤田大輔, 山田了士

    精神神経学雑誌   120 ( 4 )   343‐344 - 344   2018.4

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 統合失調症に強い関連を示した稀な遺伝子変異に基づく精神疾患の分子病態解明

    木村 大樹, 藤田 幸, 川端 猛, 森 大輔, 岩山 佳美, 岡久 祐子, 池田 匡志, 岩田 仲生, 吉川 武男, 山下 俊英, 中村 春木, 尾崎 紀夫

    先進医薬研究振興財団研究成果報告集   2017年度   80 - 81   2018.3

    　More details

    Language：Japanese   Publisher：(公財)先進医薬研究振興財団  

    researchmap

  • 統合失調症に強い関連を示した稀な遺伝子変異に基づく精神疾患の分子病態解明

    木村 大樹, 藤田 幸, 川端 猛, 森 大輔, 岩山 佳美, 岡久 祐子, 池田 匡志, 岩田 仲生, 吉川 武男, 山下 俊英, 中村 春木, 尾崎 紀夫

    先進医薬研究振興財団研究成果報告集   2017年度   80 - 81   2018.3

    　More details

    Language：Japanese   Publisher：(公財)先進医薬研究振興財団  

    researchmap

  • Clozapineによる無顆粒球症の改善後に薬剤性過敏症症候群(DIHS)をきたした1例

    原紘志, 岡久祐子, 酒本真次, 川田清宏, 高木学, 山田了士

    精神神経学雑誌   120 ( 2 )   149 - 149   2018.2

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • ストレスチェック制度の有効活用に向けた勤労者の精神疾患発症リスクに関連する神経心理学的特性の検討

    岸本真希子, 酒本真次, 岡久祐子, 高木学, 山田了士

    日本精神神経学会総会プログラム・抄録集   114th ( 2018特別号 )   S.568 - S568   2018

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 精神医学のフロンティア 統合失調症患者における認知機能障害の推定 : 多施設共同研究

    藤野 陽生, 住吉 チカ, 安田 由華, 山森 英長, 藤本 美智子, 福永 雅喜, 三浦 健一郎, 竹林 佑人, 岡田 直大, 磯村 周一, 河野 直子, 豊巻 敦人, 久我 弘典, 磯部 昌憲, 大矢 一登, 岡久 祐子, 髙木 学, 橋本 直樹, 加藤 正樹, 鬼塚 俊明, 上野 雄文, 大沼 徹, 笠井 清登, 尾崎 紀夫, 住吉 太幹, 井村 修, 橋本 亮太, COCORO

    精神神経学雑誌 = Psychiatria et neurologia Japonica   120 ( 4 )   255 - 261   2018

    　More details

    Language：Japanese   Publisher：日本精神神経学会  

    CiNii Article

    researchmap

  • 統合失調症発症に強い影響を及ぼす、頻度の低い稀な遺伝子変異を22q11.2欠失領域に存在するミエリン関連遺伝子のRTN4Rに同定した

    木村 大樹, 藤田 幸, 川端 猛, 石塚 佳奈子, Wang Chenyao, 岩山 佳美, 岡久 祐子, 久島 周, 宇野 洋太, 岡田 俊, 森川 真子, 森 大輔, 池田 匡志, 稲田 俊也, Aleksic Branko, 吉川 武男, 岩田 仲生, 中村 春木, 山下 俊英, 尾崎 紀夫

    日本生物学的精神医学会・日本神経精神薬理学会合同年会プログラム・抄録集   39回・47回   190 - 190   2017.9

    　More details

    Language：Japanese   Publisher：日本生物学的精神医学会・日本神経精神薬理学会  

    researchmap

  • A novel rare variant R292H in RTN4R affects growth cone formation and possibly contributes to schizophrenia susceptibility

    Kimura H, Fujita Y, Kawabata T, Ishizuka K, Wang C, Iwayama Y, Okahisa Y, Kushima I, Morikawa M, Uno Y, Okada T, Ikeda M, Inada T, Branko A, Mori D, Yoshikawa T, Iwata N, Nakamura H, Yamashita T, Ozaki N

    TRANSLATIONAL PSYCHIATRY   7   2017.8

    　More details

    Language：English   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.1038/tp.2017.170

    researchmap

  • Rare genetic variants in CX3CR1 and their contribution to the increased risk of schizophrenia and autism spectrum disorders

    Ishizuka K, Fujita Y, Kawabata T, Kimura H, Iwayama Y, Inada T, Okahisa Y, Egawa J, Usami M, Kushima I, Uno Y, Okada T, Ikeda M, Aleksic B, Mori D, Someya To, Yoshikawa T, Iwata N, Nakamura H, Yamashita T, Ozaki N

    TRANSLATIONAL PSYCHIATRY   7   2017.8

    　More details

    Language：English   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.1038/tp.2017.173

    researchmap

  • 日中の過眠と易怒性が初期症状であり早期診断が困難であった神経梅毒の1例

    寒川尚登, 岸本真希子, 岡久祐子, 大島悦子, 川田清宏, 山田了士, 田所功, 幡中典子, 太田康之, 阿部康二

    精神神経学雑誌   119 ( 6 )   445 - 445   2017.6

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 統合失調症発症に強い影響を及ぼす、頻度の低い稀な遺伝子変異を22q11.2欠失領域に存在するミエリン関連遺伝子のRTN4Rに同定した

    木村 大樹, 尾崎 紀夫, 藤田 幸, 川端 猛, 石塚 佳奈子, Wang Chenyao, 岩山 佳美, 岡久 祐子, 久島 周, 森川 真子, 宇野 洋太, 岡田 俊, 森 大輔, 池田 匡志, 稲田 俊也, Aleksic Branko, 吉川 武男, 岩田 仲生, 中村 春木, 山下 俊英

    精神神経学雑誌   ( 2017特別号 )   S622 - S622   2017.6

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • clozapineによる無顆粒球症の改善後に薬剤性過敏症症候群(DIHS)を来した一例

    原紘志, 原紘志, 岡久祐子, 酒本真次, 川田清宏, 高木学, 山田了士

    林精神医学研究所報   24 ( 1 )   25‐26   2017.3

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • アルツハイマー病における言語性記憶または視覚性記憶と局所脳血流の関連

    林聡, 寺田整司, 佐藤修平, 大島悦子, 栗栖海吏, 池田智香子, 岡久祐子, 高木学, 横田修, 山田了士

    老年精神医学雑誌   27 ( 増刊II )   229 - 229   2016.6

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 性同一性障害全ゲノム関連解析による病態解明

    岡久祐子, 酒本真次, 高木学, 松本洋輔, 山田了士

    先進医薬研究振興財団研究成果報告集   2015   60‐61 - 61   2016.3

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 統合失調症患者において,アリピプラゾールへの切替え方法が継続率に与える影響の検討

    大林芳明, 吉村文太, 吉村文太, 酒本真次, 岸本真希子, 岡久祐子, 武田俊彦, 高木学, 山田了士

    日本臨床精神神経薬理学会プログラム・抄録集   26th   116   2016

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 電気痙攣療法における発作の質に麻酔薬が与える影響の検討

    酒本真次, 藤原雅樹, 岸本真希子, 岡久祐子, 高木学, 山田了士

    日本臨床精神神経薬理学会プログラム・抄録集   26th   120   2016

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • PDE4B遺伝子が統合失調症の発症脆弱性と認知機能に与える影響

    酒本真次, 高木学, 岡本宗次郎, 岸本真希子, 岡久祐子, 大井一高, 大井一高, 橋本亮太, 山田了士

    日本生物学的精神医学会(Web)   38th   169 (WEB ONLY)   2016

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 抗NMDA受容体抗体が神経発達に及ぼす影響の検討

    岡本宗次郎, 酒本真次, 岸本真希子, 岡久祐子, 高木学, 山田了士

    日本生物学的精神医学会(Web)   38th   121 (WEB ONLY)   2016

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • アルツハイマー病における言語性記憶または視覚性記憶と局所脳血流の関連

    林聡, 寺田整司, 佐藤修平, 大島悦子, 栗栖海吏, 池田智香子, 岡久祐子, 高木学, 横田修, 山田了士

    Dement Jpn   29 ( 3 )   382 - 382   2015.9

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • NMDA受容体機能関連遺伝子と統合失調症患者の臨床的・社会的転帰との関連研究

    酒本 真次, 高木 学, 岡久 祐子, 水木 寛, 山田 了士

    日本生物学的精神医学会・日本神経精神薬理学会合同年会プログラム・抄録集   37回・45回   201 - 201   2015.9

    　More details

    Language：Japanese   Publisher：日本生物学的精神医学会・日本神経精神薬理学会  

    researchmap

  • FUNCTIONAL RECOVERY IN PATIENTS WITH SCHIZOPHRENIA: PREDICTING FACTORS FOR WORK OUTCOME

    Chika Sumiyoshi, Manabu Takaki, Yuko Okahisa, Taku Sato, Ichiro Sora, Keith H. Nuechterlein, Kenneth N. Subotnik, Philip D. Harvey, Tomiki Sumiyoshi

    SCHIZOPHRENIA BULLETIN   41   S192 - S192   2015.3

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 統合失調症と2型糖尿病における共通機序の解明

    高木 学, 水木 寛, 岡久 祐子, 酒本 真次

    先進医薬研究振興財団研究成果報告集   2014年度   26 - 27   2015.3

    　More details

    Language：Japanese   Publisher：(公財)先進医薬研究振興財団  

    researchmap

  • 岡山大学病院における『心のリスク外来』の取り組み

    酒本 真次, 岡久 祐子, 高木 学

    総合病院精神医学   27 ( 1 )   58 - 58   2015.1

    　More details

    Language：Japanese   Publisher：(一社)日本総合病院精神医学会  

    researchmap

  • 統合失調症患者の認知機能障害に対するクロザピンの有効性の検討

    酒本真次, 水木寛, 岡久祐子, 高木学, 山田了士

    日本臨床精神神経薬理学会プログラム・抄録集   25th   2015

    　More details

  • 統合失調症における抑うつ症状の臨床的検討 予測因子、薬物治療、社会的転帰について

    酒本 真次, 水木 寛, 岡久 祐子, 高木 学, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   24回・44回   188 - 188   2014.11

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    researchmap

  • 統合失調症に対する、アリピプラゾールの用量による有用度の検討 タイプの違う大学病院、精神科単科救急病院での比較

    高木 学, 耕野 敏樹, 吉村 文太, 酒本 真次, 水木 寛, 岡久 祐子, 児玉 匡史, 来住 由樹, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   24回・44回   161 - 161   2014.11

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    researchmap

  • UCSD日常生活技能簡易評価尺度(UPSA-B)の開発 日本語版統合失調症と健常者の比較

    住吉 チカ, 高木 学, 岡久 祐子, 住吉 太幹

    日本心理学会大会発表論文集   78回   404 - 404   2014.8

    　More details

    Language：Japanese   Publisher：(公社)日本心理学会  

    researchmap

  • THE UCSD PERFORMANCE-BASED SKILLS ASSESSMENT-BRIEF JAPANESE VERSION (UPSA-B_J): DISCRIMINATIVE VALIDITY FOR SCHIZOPHRENIA

    Chika Sumiyoshi, Manabu Takaki, Yuko Okahisa, Thomas Patterson, Philip D. Harvey, Tomiki Sumiyoshi

    SCHIZOPHRENIA RESEARCH   153   S266 - S266   2014.4

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Human Rho guanine nucleotide exchange factor 11の統合失調症患者における遺伝子関連解析と機能解析

    水木寛, 高木学, 岡久祐子, 酒本真次, 氏家寛, 内富庸介

    日本生物学的精神医学会誌   2014

    　More details

  • 統合失調症患者の臨床経過と転帰に関与する遺伝要因の検討

    酒本真次, 高木学, 岡久祐子, 水木寛, 稲垣正俊, 氏家寛, 池田匡志, 岩田仲生, 内富庸介

    日本生物学的精神医学会誌   2014

    　More details

  • 統合失調症発症前駆期におけるバイオマーカーの検索

    岡久祐子, 池田匡志, 酒本真次, 高木学, 氏家寛, 岩田仲生, 内富庸介

    日本生物学的精神医学会誌   2014

    　More details

  • 重度の2型糖尿病にクロザピンを使用した治療抵抗性統合失調症の2症例

    酒本 真次, 馬庭 真利子, 竹之下 慎太郎, 水木 寛, 岡久 祐子, 高木 学, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   23回・43回   180 - 180   2013.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    researchmap

  • 統合失調症に併発する抑うつが、社会的転帰、薬物療法に与える影響

    高木 学, 水木 寛, 酒本 真次, 岡久 祐子, 児玉 匡史, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   23回・43回   218 - 218   2013.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    researchmap

  • 薬の使い方シリーズ Blonanserinを使いこなす(第9回) 統合失調症治療におけるblonanserinへの期待 高プロラクチン血症を中心に

    岡久 祐子, 高木 学

    臨床精神薬理   16 ( 9 )   1385 - 1391   2013.9

    　More details

    Language：Japanese   Publisher：(株)星和書店  

    researchmap

  • 依存のゲノム科学 テーラーメイド依存治療に向けて 覚せい剤依存症のゲノム解析

    岡久 祐子

    日本アルコール・薬物医学会雑誌   48 ( 4 )   95 - 95   2013.8

    　More details

    Language：Japanese   Publisher：(一社)日本アルコール・アディクション医学会  

    researchmap

  • 遷延した意識障害が体重増加とともに改善した神経性無食欲症の1例

    光井 祐子, 藤原 雅樹, 岡久 祐子, 児玉 匡史, 岡部 伸幸, 内富 庸介

    精神神経学雑誌   115 ( 6 )   684 - 684   2013.6

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 統合失調症以外における、非鎮静系AripiprazoleとBlonanserinの有用性

    高木 学, 水木 寛, 酒本 真次, 藤原 雅樹, 岡久 祐子, 井上 真一郎, 児玉 匡史, 内富 庸介

    精神神経学雑誌   ( 2013特別 )   S - 363   2013.5

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 統合失調症に併発する抑うつが、社会性、薬物療法に与える影響

    高木 学, 水木 寛, 酒本 真次, 藤原 雅樹, 岡久 祐子, 児玉 匡史, 内富 庸介

    精神神経学雑誌   ( 2013特別 )   S - 525   2013.5

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 統合失調症認知機能簡易評価尺度日本語版(BACS-J)標準化の試み

    兼田 康宏, 住吉 太幹, 中込 和幸, 池澤 聰, 大森 哲郎, 古郡 規雄, 功刀 浩, 松尾 淳子, 宮本 聖也, 中村 純, 久住 一郎, 岡久 祐子, 小林 正義, 岡村 愛子, 鈴木 雄太郎, 管 心, 尾崎 紀夫, 吉田 泰介, 長田 泉美, 加藤 淳一, 浦田 暁菜, 佐久間 寛之, 永嶌 朋久, 石郷岡 純, 船橋 英樹, 羽下 路子, 赤澤 将文, 芳賀 大輔, 羽鳥 乃路, 原田 俊樹, 中谷 真樹, 児嶋 亮, 上原 優子, 松本 香子

    精神医学   55 ( 2 )   167 - 175   2013.2

    　More details

  • Association between the tyrosine hydroxylase gene and patients with methamphetamine dependence

    Y. Okahisa, M. Kishimoto, S. Sakamoto, Y. Mizuki, M. Takaki, M. Kodama, H. Ujike, Y. Uchitomi

    EUROPEAN NEUROPSYCHOPHARMACOLOGY   22   S401 - S402   2012.10

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Association between the fyn kinase gene and patients with methamphetamine psychosis

    Y. Okahisa, S. Sakamoto, M. Kodama, M. Takaki, Y. Mizuki, H. Ujike, Y. Uchitomi

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   15   74 - 74   2012.6

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 統合失調症維持期を中心とした、非鎮静系抗精神病薬aripiprazole、blonanserinの比較 薬理学的特性から使い分けを考える

    高木 学, 岡久 祐子, 児玉 匡史, 北川 航平, 水木 寛, 酒本 真次, 氏家 寛, 内富 庸介

    臨床精神薬理   15 ( 6 )   949 - 959   2012.6

    　More details

    Language：Japanese   Publisher：(株)星和書店  

    researchmap

  • 統合失調症と覚醒剤誘発性精神病の遺伝学的共通性

    池田 匡志, 岡久 祐子, 福生 泰久, アレクシッチ・ブランコ, Gida J, 尾崎 紀夫, 岩田 仲生

    精神神経学雑誌   ( 2012特別 )   S - 488   2012.5

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 重度深部静脈血栓症を併発した悪性カタトニアに下大静脈フィルターを留置しmECTを施行しえた一例

    酒本 真次, 水木 寛, 岡久 祐子, 高木 学, 児玉 匡史, 内富 庸介

    精神神経学雑誌   ( 2012特別 )   S - 457   2012.5

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • 薬物依存の基礎から臨床、そして日常診療との関わりについて 薬物乱用・依存の遺伝子研究

    岡久 祐子

    精神神経学雑誌   ( 2012特別 )   S - 392   2012.5

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

  • ASSOCIATION BETWEEN THE ARHGEF11 GENE AND SCHIZOPHRENIA IN A JAPANESE POPULATION

    Yutaka Mizuki, Manabu Takaki, Yuko Okahisa, Masafumi Kodama, Hiroshi Ujike, Yosuke Uchitomi

    SCHIZOPHRENIA RESEARCH   136   S227 - S227   2012.4

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • A POLYMORPHISM IN THE CNR1 GENE IS ASSOCIATED WITH GENE EXPRESSION AND SCHIZOPHRENIA

    Yuko Okahisa, Hiroshi Ujike, Masafumi Kodama, Manabu Takaki, Yutaka Mizuki, Shinji Sakamoto, Nao Imai, Yosuke Uchitomi, Makoto Arai, Masanari Itokawa

    SCHIZOPHRENIA RESEARCH   136   S228 - S228   2012.4

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • うつ状態に対するlamotrigineの急性効果の検討

    藤原 雅樹, 児玉 匡史, 岡久 祐子, 高木 学, 水木 寛, 酒本 真次, 松本 洋輔, 内富 庸介

    臨床精神薬理   15 ( 4 )   551 - 559   2012.4

    　More details

    Language：Japanese   Publisher：(株)星和書店  

    researchmap

  • PCM1遺伝子と統合失調症の関連解析

    酒本真次, 高木学, 岡久祐子, 水木寛, 児玉匡史, 氏家寛, 内富庸介

    日本生物学的精神医学会誌   23 ( Supplement )   2012

    　More details

  • 統合失調症における社会生活機能障害の評価・支援-MATRICS-CCB日本語版による認知機能障害の評価と治療計画への応用-MATRICSコンセンサス認知機能評価バッテリー日本語版の計量心理学的特性の検討

    兼田康宏, 大森哲郎, 岡久祐子, 住吉太幹, 朴盛弘, 高木学, 中込和幸, 曽良一郎

    統合失調症における社会生活機能障害の評価・支援-MATRICS-CCB日本語版による認知機能障害の評価と治療計画への応用 平成23年度 総括・分担研究報告書   2012

    　More details

  • 統合失調症における社会生活機能障害の評価・支援-MATRICS-CCB日本語版による認知機能障害の評価と治療計画への応用-MATRICSコンセンサス認知機能評価バッテリー日本語版の計量心理学的特性に関する研究

    兼田康宏, 大森哲郎, 岡久祐子, 住吉太幹, 朴盛弘, 高木学, 中込和幸, 曽良一郎

    統合失調症における社会生活機能障害の評価・支援-MATRICS-CCB日本語版による認知機能障害の評価と治療計画への応用 平成21-23年度 総合研究報告書   2012

    　More details

  • 2型糖尿病疾患候補遺伝子ARHGEF11の統合失調症における相関解析

    水木寛, 高木学, 酒本真次, 岡久祐子, 児玉匡史, 氏家寛, 内富庸介

    日本生物学的精神医学会誌   23 ( Supplement )   2012

    　More details

  • 気分障害へのラモトリギンの効果の検討

    児玉 匡史, 酒本 真次, 水木 寛, 岡久 祐子, 高木 学, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   21回・41回   202 - 202   2011.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    researchmap

  • 統合失調症の認知機能障害に対し抑肝散が有効であった1例

    酒本 真次, 氏家 寛, 高木 学, 今井 奈緒, 水木 寛, 岡久 祐子, 児玉 匡史, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   21回・41回   154 - 154   2011.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    J-GLOBAL

    researchmap

  • 統合失調症維持期における、非鎮静系抗精神病薬アリピプラゾールとブロナンセリンの比較

    高木 学, 児玉 匡史, 岡久 祐子, 氏家 寛, 水木 寛, 酒本 真次, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   21回・41回   163 - 163   2011.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    J-GLOBAL

    researchmap

  • 統合失調症以外の疾患に対する、非鎮静系抗精神病薬アリピプラゾールとブロナンセリンの使用状況と有用性の検討

    高木 学, 児玉 匡史, 岡久 祐子, 氏家 寛, 水木 寛, 酒本 真次, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   21回・41回   163 - 163   2011.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    researchmap

  • Blonanserinへの切り替えによりRisperidoneによる高プロラクチン血症が改善した統合失調症の4例

    岡久 祐子, 酒本 真次, 水木 寛, 高木 学, 和気 洋介, 児玉 匡史, 氏家 寛, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   21回・41回   175 - 175   2011.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    J-GLOBAL

    researchmap

  • RisperidoneからBlonanserineへの切り替えにより、統合失調症の陽性症状に加え、ジスキネジア、ジストニア、過食、QT延長に改善が見られた一例

    水木 寛, 高木 学, 児玉 匡史, 岡久 祐子, 氏家 寛, 酒本 真次, 内富 庸介

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   21回・41回   193 - 193   2011.10

    　More details

    Language：Japanese   Publisher：日本臨床精神神経薬理学会・日本神経精神薬理学会  

    J-GLOBAL

    researchmap

  • Improvement of serum prolactin after switching to blonanserin from risperidone in patients with schizophrenia: report of four cases

    Y. Okahisa, M. Takaki, Y. Wake, M. Kodama, H. Ujike

    EUROPEAN NEUROPSYCHOPHARMACOLOGY   21   S476 - S476   2011.9

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Mirtazapineにより早期にうつ状態が改善し併せてベンゾジアゼピン系睡眠薬と抗不安薬を減量することが可能となった3症例

    高木 学, 折田 暁尚, 岡久 祐子, 水木 寛, 高橋 茂, 児玉 匡史, 内富 庸介

    臨床精神薬理   14 ( 9 )   1561 - 1565   2011.9

    　More details

    Language：Japanese   Publisher：(株)星和書店  

    researchmap

  • 高齢者うつ病にmirtazapine使用後、せん妄を来した4例

    井上 真一郎, 岡部 伸幸, 矢野 智宣, 中村 真之, 牧 安紀, 岡久 祐子, 高木 学, 児玉 匡史, 松本 洋輔, 寺田 整司, 内富 庸介

    臨床精神薬理   14 ( 6 )   1057 - 1062   2011.6

    　More details

    Language：Japanese   Publisher：(株)星和書店  

    researchmap

  • 非鎮静系抗精神病薬aripiprazole、blonanserinの可能性 急性期、維持期における改善例を通じて見えてくるもの

    高木 学, 折田 暁尚, 五島 淳, 児玉 匡史, 岡久 祐子, 高橋 茂, 中島 豊爾, 内富 庸介

    臨床精神薬理   13 ( 9 )   1771 - 1777   2010.9

    　More details

    Language：Japanese   Publisher：(株)星和書店  

    researchmap

  • 【薬物依存症 薬物依存症のトレンド】薬物依存症の関連遺伝子

    高木 学, 岡久 祐子, 氏家 寛

    日本臨床   68 ( 8 )   1451 - 1456   2010.8

    　More details

  • ASSOCIATION BETWEEN THE SELENBP1 GENE AND SCHIZOPHRENIA IN A JAPANESE POPULATION

    Yuko Okahisa, Eriko Yokobayashi, Takeshi Lshihara, Masafumi Kodama, Manabu Takaki, Hiroshi Ujike

    SCHIZOPHRENIA RESEARCH   117 ( 2-3 )   450 - 450   2010.4

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    DOI： 10.1016/j.schres.2010.02.836

    Web of Science

    researchmap

  • 【関連遺伝子と精神疾患 全ゲノム解析はどこまでわかったか】薬物依存

    氏家 寛, 岡久 祐子, 高木 学

    精神科   16 ( 2 )   161 - 166   2010.2

    　More details

    Language：Japanese   Publisher：(有)科学評論社  

    全ゲノム解析の主役が連鎖解析から全ゲノム相関解析(GWAS)に移り、数十万の一塩基置換多型(SNP)の解析が可能となり、薬物依存脆弱性に関与する可能性のある多くの遺伝子が発見されるようになった。アルコール依存症、ニコチン依存症、違法性薬物依存症の全ゲノム解析について概説した。また、薬物依存関連遺伝子のデータベース、遺伝子解析から推定される薬物依存神経機序を図に示した。

    researchmap

  • 覚せい剤精神病におけるグルタミン酸神経伝達関連遺伝子解析

    氏家 寛, 小高 辰也, 岸本 真希子, 岡久 祐子, 高木 学, 児玉 匡史, 稲田 俊也, 山田 光彦, 内村 直尚, 岩田 仲生, 曽良 一郎, 伊豫 雅臣, 尾崎 紀夫, 黒田 重利

    精神薬療研究年報   ( 41 )   25 - 26   2009.3

    　More details

    Language：Japanese   Publisher：(公財)先進医薬研究振興財団  

    researchmap

  • 【覚せい剤依存症】覚せい剤依存症・精神病ゲノム因子の最新知見

    氏家 寛, 岡久 祐子

    最新精神医学   14 ( 2 )   127 - 132   2009.3

    　More details

    Language：Japanese   Publisher：(株)世論時報社  

    researchmap

  • Analyses of genetic factors in olanzapine-induced weight gain in schizophrenic patients

    H. Ujike, A. Nomura, Y. Morita, Y. Okahisa, T. Kotaka, M. Kodama, T. Ishiahara, S. Kuroda

    EUROPEAN NEUROPSYCHOPHARMACOLOGY   18   S417 - S417   2008.8

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 依存性薬物および未規制薬物による神経毒性と精神病の発現機序」3年間のまとめ 多剤乱用の実態と物質誘発性精神病の遺伝子リスクファクターの解明

    氏家寛, 森田幸孝, 大谷恭平, 岡久祐子, 岸本真希子, 小高辰也, 森尾亜希子, 稲田俊也, 原野陸正, 小宮山徳太郎, 堀達, 山田光彦, 関根吉統, 曽良一郎, 岩田仲生, 伊豫雅臣, 尾崎紀夫, 黒田重利

    依存性薬物および未規制薬物による神経毒性と精神病の発現機序 平成18年度 総括研究報告書 平成16-18年度 総合研究報告書   2007

    　More details

  • The frizzled 3 (FZD3) gene is associated with methamphetamine psychosis

    Makiko Kishimoto, Hiroshi Ujike, Yuji Tanaka, Kyohei Otani, Yukitaka Morita, Akiko Morio, Yuko Okahisa, Tatsuya Kotaka, Mutsuo Harano, Toshiya Inada, Mitsuhiko Yamada, Tokutaro Komiyama, Toru Hori, Yoshimoto Sekine, Nakao Iwata, Ichiro Sora, Masaomi Iyo, Norio Ozaki, Shigetoshi Kuroda

    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS   141B ( 7 )   807 - 807   2006.10

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Association study between the NrCAM gene and patients with methamphetamine use disorders

    Yuko Okahisa, Hiroshi Ujike, Yuji Tanaka, Kyohei Otani, Yukitaka Morita, Makiko Kishimoto, Akiko Morio, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Toru Hori, Mitsuhiko Yamada, Yoshimoto Sekine, Nakao Iwata, Masaomi Iyo, Ichiro Sora, Norio Ozaki, Shigetoshi Kuroda

    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS   141B ( 7 )   806 - 807   2006.10

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • NrCAM遺伝子多型と覚醒剤精神病の関連研究

    岡久 祐子, 氏家 寛, 田中 有史, 大谷 恭平, 森田 幸孝, 岸本 真希子, 森尾 亜希子, 小高 辰也, 稲田 俊也, 原野 睦生, 小宮山 徳太郎, 堀 達, 山田 光彦, 関根 吉統, 岩田 仲生, 伊豫 雅臣, 曽良 一郎, 尾崎 紀夫, 黒田 重利

    神経化学   45 ( 2-3 )   398 - 398   2006.8

    　More details

    Language：Japanese   Publisher：日本神経化学会  

    J-GLOBAL

    researchmap

  • Association study between the serotonin 1B receptor gene and methamphetamine psychosis

    KISHIMOTO MAKIKO, UJIIE HIROSHI, TANAKA YUJI, OTANI KYOHEI, MORIO AKIKO, OKAHISA YUKO, KOTAKA TATSUYA, HARANO MUTSUO, INADA TOSHIYA, YAMADA MITSUHIKO, KOMIYAMA TOKUTARO, HORI TOORU, SEKINE YOSHIMOTO, IWATA NAKAO, SONE ICHIRO, IYO MASAOMI, OZAKI NORIO, KURODA SHIGETOSHI

    神経化学   45 ( 2-3 )   397 - 397   2006.8

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 更年期の全般性不安障害

    岡久 祐子, 岡部 健雄

    倉敷中央病院年報   68   81 - 85   2006.3

    　More details

    Language：Japanese   Publisher：(公財)大原記念倉敷中央医療機構倉敷中央病院  

    当院で経験した更年期の全般性不安障害4例について報告した.4例はいずれも50歳代女性で,不安とそれに伴う体調不良,動悸,食欲低下,不眠などの不定愁訴がみられた.きっかけは家族の病気や死亡,介護,子供の進学・就職や夫の単身赴任,自分自身の病気や退職などであった.4例中3例では家族の協力が十分に得られ,心理療法・薬物療法を導入でき,比較的早期に症状の軽快がみられたが,残り1例では夫や子供の協力が皆無で家庭環境の調節は難しく,心理療法や薬物療法の導入は困難で,通院を中断してしまった.更年期女性の全般性不安障害は,患者の環境変化や性格背景を把握し,心理療法と薬物療法を併用して治療を行うことが必要であると考えられた

    researchmap

  • 依存性薬物および未規制薬物による神経毒性と精神病の発現機序 多剤乱用の実態と物質誘発性精神病の遺伝子リスクファクターの解明 FZD-3,XBP-1およびFAAH遺伝子の検討

    氏家寛, 岸本真希子, 森田幸孝, 大谷恭平, 岡久祐子, 森尾亜希子, 稲田俊也, 原野陸正, 小宮山徳太郎, 堀達, 山田光彦, 関根吉統, 曽良一郎, 岩田仲生, 伊豫雅臣, 尾崎紀夫, 黒田重利

    依存性薬物および未規制薬物による神経毒性と精神病の発現機序 平成17年度 総括研究報告書   2006

    　More details

  • 水頭症治療後に統合失調症を発症した症例

    氏福 健太, 平尾 朋仁, 山下 弘己, 岡久 祐子

    山口県医学会誌   ( 38 )   100 - 100   2004.3

    　More details

    Language：Japanese   Publisher：(一社)山口県医師会  

    researchmap

  • 統合失調症様症状を呈した22q11.2欠失症候群の1例

    門家 千穂, 氏家 寛, 和気 洋介, 岡久 祐子, 黒田 重利

    精神医学   46 ( 2 )   187 - 190   2004.2

    　More details

    Language：Japanese   Publisher：(株)医学書院  

    24歳女.5歳時に精神遅滞を指摘された.成績は不良で,高校中退後は家事手伝いをしていた.自発性の低下がみられ,何かしている途中でボーッと止まってしまうようになった.「首や目が勝手にキョロキョロ動かされる」との訴えも出現し,入院した.心血管奇形,特異顔貌,低カルシウム血症,鼻咽腔閉鎖不全,精神遅滞,血小板減少がみられることより22q11.2欠失症候群を疑い,FISH法により確定診断した.クエチアピンを開始し,約2週間頃より次第に対人緊張が軽減し表情が穏やかになり,母親以外の者とも談笑できるようになった.精神遅滞のため病棟の規則などの了解が悪く,食事時間に戻ってこなかったり,夜遅く大声でしゃべったりと,時に問題行動がみられることもあった.病的精神症状がほぼ消失したため入院約3ヵ月後に退院した.バセドウ病は抗甲状腺剤で治療を行っていたが退院時に甲状腺機能はまだ正常域には戻ってはいなかった

    researchmap

    Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2004&ichushi_jid=J00749&link_issn=&doc_id=20040217080014&doc_link_id=10.11477%2Fmf.1405100438&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1405100438&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • 友人の自殺をきっかけに二人でリストカットを繰り返した女子高校生

    岡久 祐子, 藤本 明

    総合病院精神医学   15 ( Suppl. )   S164 - S164   2003.11

    　More details

    Language：Japanese   Publisher：(一社)日本総合病院精神医学会  

    researchmap

  • 思春期行為障害の入院治療

    岡久 祐子, 大西 勝, 佐藤 俊樹, 黒田 重利

    精神神経学雑誌   104 ( 7 )   612 - 613   2002.7

    　More details

    Language：Japanese   Publisher：(公社)日本精神神経学会  

    researchmap

▼display all

Research Projects

  • 腸内細菌叢のマルチオミクス解析による統合失調症の病態解明

    Grant number：21K07481  2021.04 - 2024.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    岡久 祐子

    　 More details

    Grant amount：\4030000 （ Direct expense: \3100000 、 Indirect expense：\930000 ）

    統合失調症の病態に免疫学的な機序が関わることがこれまでの遺伝子解析や疫学研究で示唆されている。腸内細菌叢は宿主免疫系を制御することで様々な生理機能や病態形成に関わっているが、腸内細菌叢とその代謝産物はbrain-gut-microbiota axis (脳－腸－腸内細菌軸)を介して中枢神経系の活動に影響し、統合失調症の病態にも関与するとして、近年注目を集めている。本研究では、日本人統合失調症患者を対象として腸内細菌叢のメタボローム解析を行い、患者で変化している個々の細菌種と代謝物質との相関について解析し、統合失調症の病態解明の手掛かりを得ることを目的とする。
    解析の対象は、岡山大学病院精神科神経科を受診した外来または入院患者で、DSM-5及ICD-10を用いて統合失調症と診断された18歳～65歳までの患者と年齢、性を一致させた健常対照者で、研究の趣旨を説明し同意の得られた対象者から糞便採取を行う。統合失調症患者の臨床症状や重症度、認知機能との関連も検討する。検討に用いる評価尺度である陽性・陰性症状評価尺度(PANSS)、全般的機能評価尺度(GAF)、臨床的全般改善度(CGI)、統合失調症認知機能簡易評価尺度(BACS)、Wisconsin Card Sorted Test、前頭葉機能検査(FAB)、Japanese Adult Reading Test 、Wecheler Adult Intelligence Scale -Reviced (WAIS-R)等を統合失調症患者に施行した。

    researchmap

  • 腸内細菌叢の網羅的解析による統合失調症の病態解明

    Grant number：18K07601  2018.04 - 2023.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    岡久 祐子

    　 More details

    Grant amount：\4290000 （ Direct expense: \3300000 、 Indirect expense：\990000 ）

    統合失調症の病態に免疫学的な機序が関わることがこれまでの遺伝子解析や疫学研究で示唆されている。脳腸間の情報伝達において重要な役割を担っている腸内細菌叢は、宿主免疫系を制御することで様々な生理機能や病態形成に関わっている。これまでの研究で、腸内細菌叢は脳の発達や機能に関与することが示唆さ
    れ、宿主の行動特性に変化をもたらすこと、宿主のストレスで変化することが示され、統合失調症の病態に腸内細菌叢が関与している可能性が推測される。近年の次世代シーケンサーの発達により腸内細菌叢の詳細な解析が可能になっており、本研究では、日本人統合失調症患者を対象として、次世代シーケンサーによる
    腸内細菌叢の詳細な解析を行い、統合失調症の病態解明の手掛かりを得ることを目的とする。
    解析の対象は、岡山大学病院精神科神経科を受診した外来または入院患者で、DSM-5及ICD-10を用いて統合失調症と診断された18歳～65歳までの患者と年齢、性を一致させた健常対照者で、研究の趣旨を説明し同意の得られた対象者から糞便採取を行う。統合失調症患者の臨床症状や重症度、認知機能との関連も検討する。検討に用いる評価尺度である陽性・陰性症状評価尺度(PANSS)、全般的機能評価尺度(GAF)、臨床的全般改善度(CGI)、統合失調症認知機能簡易評価尺度
    (BACS)、Wisconsin Card Sorted Test、前頭葉機能検査(FAB)、Japanese Adult Reading Test 、Wecheler Adult Intelligence Scale -Reviced (WAIS-R)等を統合失調症患者に施行した。

    researchmap

  • Analysis of molecular pathophysiology of gender identity disorder using microarray method

    Grant number：15K09806  2015.04 - 2019.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Okahisa Yuko

    　 More details

    Grant amount：\4810000 （ Direct expense: \3700000 、 Indirect expense：\1110000 ）

    The purpose of this study is to reveal the molecular pathophysiology of gender identity disorder. We conducted whole-genome analysis of 206 female-to-male trans-sexual individuals and 1557 control subjects using Japonica array but failed to identify pathogenesis of gender identity disorder. We intend to perform further research using larger samples.

    researchmap

  • Analysis of molecular pathophysiology of gender identity disorder using microarray method

    Grant number：25861007  2013.04 - 2015.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    OKAHISA YUKO

    　 More details

    Grant amount：\4030000 （ Direct expense: \3100000 、 Indirect expense：\930000 ）

    The purpose of this study is to reveal the molecular pathophysiology of gender identity disorder. We conducted whole-genome analysis of 96 female-to-male trans-sexual individuals using Japonica array but failed to identify pathogenesis of gender identity disorder. We intend to perform genotype imputation analysis in further study.

    researchmap

  • Development of a method for diagnosis of the prodromal stage of schizophrenia

    Grant number：23791334  2011 - 2012

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    OKAHISA Yuko

    　 More details

    Grant amount：\4550000 （ Direct expense: \3500000 、 Indirect expense：\1050000 ）

    The purpose of this study was to develop a method for diagnosisof schizophrenia in the prodromal stage. We evaluated the symptoms of eight subjects who were at risk of developing schizophrenia for one year. Then, we analyzed their whole-gene expression profiles using a microarray but failed to find any significant genome-wide difference between the groups that developed of schizophrenia and those who did not. A larger sample should be investigated in further studies.

    researchmap

 

Class subject in charge

  • Neuropsychiatry (Core Clinical Practice) （2025academic year） special  - その他

  • Neuropsychiatry （2025academic year） Fourth semester  - 水7

  • Practicals: Neuropsychiatry （2025academic year） special  - その他

  • Research Project: Neuropsychiatry （2025academic year） special  - その他

  • Lecture and Research Projects: Neuropsychiatry I （2025academic year） special  - その他

  • Lecture and Research Projects: Neuropsychiatry II （2025academic year） special  - その他

  • Mental Disorder （2025academic year） special  - その他

  • Elective Clinical Practice (Neuropsychiatry) （2025academic year） special  - その他

  • Neuropsychiatry (Core Clinical Practice) （2024academic year） special  - その他

  • Neuropsychiatry （2024academic year） Fourth semester  - 水6

  • Practicals: Neuropsychiatry （2024academic year） special  - その他

  • Research Project: Neuropsychiatry （2024academic year） special  - その他

  • Research Projects and Practicals: Neuropsychiatry I （2024academic year） special  - その他

  • Lecture and Research Projects: Neuropsychiatry I （2024academic year） special  - その他

  • Research Projects and Practicals: Neuropsychiatry II （2024academic year） special  - その他

  • Lecture and Research Projects: Neuropsychiatry II （2024academic year） special  - その他

  • Mental Disorder （2024academic year） special  - その他

  • Elective Clinical Practice (Neuropsychiatry) （2024academic year） special  - その他

  • Neuropsychiatry (Core Clinical Practice) （2023academic year） special  - その他

  • Neuropsychiatry （2023academic year） Fourth semester  - 水6

  • Practicals: Neuropsychiatry （2023academic year） special  - その他

  • Research Project: Neuropsychiatry （2023academic year） special  - その他

  • Research Projects and Practicals: Neuropsychiatry I （2023academic year） special  - その他

  • Lecture and Research Projects: Neuropsychiatry I （2023academic year） special  - その他

  • Research Projects and Practicals: Neuropsychiatry II （2023academic year） special  - その他

  • Lecture and Research Projects: Neuropsychiatry II （2023academic year） special  - その他

  • Mental Disorder （2023academic year） special  - その他

  • Elective Clinical Practice (Neuropsychiatry) （2023academic year） special  - その他

  • Neuropsychiatry (Core Clinical Practice) （2022academic year） special  - その他

  • Research Projects and Practicals: Neuropsychiatry I （2022academic year） special  - その他

  • Lecture and Research Projects: Neuropsychiatry I （2022academic year） special  - その他

  • Research Projects and Practicals: Neuropsychiatry II （2022academic year） special  - その他

  • Lecture and Research Projects: Neuropsychiatry II （2022academic year） special  - その他

  • Mental Disorder （2022academic year） special  - その他

  • Elective Clinical Practice (Neuropsychiatry) （2022academic year） special  - その他

  • Neuropsychiatry (Core Clinical Practice) （2021academic year） special  - その他

  • Mental Disorder （2021academic year） special  - その他

  • Neuropsychiatry (Core Clinical Practice) （2020academic year） special  - その他

  • Mental Disorder （2020academic year） special  - その他

▼display all